SEC Filing | Prestige Consumer Healthcare Inc.

View:

Download DOC

Download PDF

Download XLS

Download XBRL

PBH 10Q December 31 2011

U. S. SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 10-Q



[ X ]	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2011



[ ]	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____ to _____

Commission File Number: 001-32433

PRESTIGE BRANDS HOLDINGS, INC.

(Exact name of Registrant as specified in its charter)



Delaware		20-1297589
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

90 North Broadway

Irvington, New York 10533

(Address of Principal Executive Offices, including zip code)

(914) 524-6810

(Registrant's telephone number, including area code)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes x No o

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):



Large accelerated filer o		Accelerated filer x
Non-accelerated filer o	(Do not check if a smaller reporting company)	Smaller reporting company o

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes o No x

As of February 6, 2012, there were 50,433,268 shares of common stock outstanding.

Prestige Brands Holdings, Inc.

Form 10-Q

Index



PART I.	FINANCIAL INFORMATION

Item 1.	Consolidated Financial Statements
	Consolidated Statements of Operations for the three and nine months ended December 31, 2011 and 2010 (unaudited)	2
	Consolidated Balance Sheets as of December 31, 2011 and March 31, 2011 (unaudited)	3
	Consolidated Statements of Cash Flows for the nine months ended December 31, 2011 and 2010 (unaudited)	4
	Notes to Consolidated Financial Statements	5

Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	35

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	52

Item 4.	Controls and Procedures	52

PART II.	OTHER INFORMATION

Item 1.	Legal Proceedings	52

Item 6.	Exhibits	52

	Signatures	53

Trademarks and Trade Names

Trademarks and trade names used in this Quarterly Report on Form 10-Q are the property of Prestige Brands Holdings, Inc. or its subsidiaries, as the case may be. We have italicized our trademarks or trade names when they appear in this Quarterly Report on Form 10-Q.

-1-


PART I	FINANCIAL INFORMATION


ITEM 1.	CONSOLIDATED FINANCIAL STATEMENTS

Prestige Brands Holdings, Inc.

Consolidated Statements of Operations

(Unaudited)



	Three Months Ended December 31,					Nine Months Ended December 31,
(In thousands, except per share data)	2011			2010		2011			2010
Revenues
Net sales	$	105,799		$	90,077	$	304,678		$	238,086
Other revenues	451			531		2,411			2,061
Total revenues	106,250			90,608		307,089			240,147

Cost of Sales
Cost of sales (exclusive of depreciation shown below)	51,128			46,596		148,193			115,574
Gross profit	55,122			44,012		158,896			124,573

Operating Expenses
Advertising and promotion	15,274			13,049		38,580			28,775
General and administrative	13,655			15,426		32,366			30,941
Depreciation and amortization	2,563			2,513		7,683			7,336
Total operating expenses	31,492			30,988		78,629			67,052

Operating income	23,630			13,024		80,267			57,521

Other (income) expense
Interest income	(1		)	—		(4		)	—
Interest expense	8,117			7,674		24,977			18,508
Gain on settlement	—			—		(5,063		)	—
Loss on extinguishment of debt	—			—		—			300
Total other expense	8,116			7,674		19,910			18,808

Income from continuing operations before income taxes	15,514			5,350		60,357			38,713
Provision for income taxes	6,004			3,204		23,130			15,948
Income from continuing operations	9,510			2,146		37,227			22,765

Discontinued Operations
Income from discontinued operations, net of income tax	—			32		—			591
Loss on sale of discontinued operations, net of income tax	—			—		—			(550		)
Net income	$	9,510		$	2,178	$	37,227		$	22,806

Basic earnings per share:
Income from continuing operations	$	0.19		$	0.04	$	0.74		$	0.46
Income from discontinued operations and loss on sale of discontinued operations	—			—		—			—
Net income	$	0.19		$	0.04	$	0.74		$	0.46

Diluted earnings per share:
Income from continuing operations	$	0.19		$	0.04	$	0.73		$	0.45
Income from discontinued operations and loss on sale of discontinued operations	—			—		—			—
Net income	$	0.19		$	0.04	$	0.73		$	0.45

Weighted average shares outstanding:
Basic	50,307			50,085		50,256			50,059
Diluted	50,684			50,533		50,667			50,260

See accompanying notes.

-2-

Prestige Brands Holdings, Inc.

Consolidated Balance Sheets

(Unaudited)



(In thousands) Assets	December 31, 2011			March 31, 2011
Current assets
Cash and cash equivalents	$	4,439		$	13,334
Accounts receivable, net	50,163			44,393
Inventories	43,579			39,751
Deferred income tax assets	5,540			5,292
Prepaid expenses and other current assets	2,162			4,812
Total current assets	105,883			107,582

Property and equipment, net	1,238			1,444
Goodwill	153,696			154,896
Intangible assets, net	779,242			786,361
Other long-term assets	5,788			6,635

Total Assets	$	1,045,847		$	1,056,918

Liabilities and Stockholders' Equity
Current liabilities
Accounts payable	$	23,977		$	21,615
Accrued interest payable	5,181			10,313
Other accrued liabilities	23,905			22,280
Total current liabilities	53,063			54,208

Long-term debt
Principal amount	434,000			492,000
Less unamortized discount	(4,368		)	(5,055		)
Long-term debt, net of unamortized discount	429,632			486,945

Deferred income tax liabilities	161,502			153,933

Total Liabilities	644,197			695,086

Commitments and Contingencies — Note 17

Stockholders' Equity
Preferred stock - $0.01 par value
Authorized - 5,000 shares
Issued and outstanding - None	—			—
Common stock - $0.01 par value
Authorized - 250,000 shares
Issued - 50,433 shares at December 31, 2011 and 50,276 shares at March 31, 2011	504			503
Additional paid-in capital	390,863			387,932
Treasury stock, at cost - 181 shares at December 31, 2011 and 160 shares at March 31, 2011	(687		)	(416		)
Accumulated other comprehensive loss, net of tax	(70		)	—
Retained earnings (accumulated deficit)	11,040			(26,187		)
Total Stockholders' Equity	401,650			361,832

Total Liabilities and Stockholders' Equity	$	1,045,847		$	1,056,918

See accompanying notes.

-3-

Prestige Brands Holdings, Inc.

Consolidated Statements of Cash Flows

(Unaudited)



	Nine Months Ended December 31,
(In thousands)	2011			2010
Operating Activities
Net income	$	37,227		$	22,806
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	7,683			7,565
Loss on sale of discontinued operations	—			890
Deferred income taxes	7,321			5,591
Amortization of deferred financing costs	847			767
Stock-based compensation costs	2,360			2,751
Loss on extinguishment of debt	—			300
Amortization of debt discount	687			480
Loss on disposal of equipment	—			131
Changes in operating assets and liabilities
Accounts receivable	(5,816		)	7,330
Inventories	(3,850		)	2,814
Inventories held for sale	—			1,114
Prepaid expenses and other current assets	2,650			3,166
Accounts payable	2,392			(1,054		)
Accrued liabilities	(3,508		)	7,008
Net cash provided by operating activities	47,993			61,659

Investing Activities
Purchases of equipment	(358		)	(405		)
Proceeds from sale of discontinued operations	—			4,122
Acquisition of Blacksmith, net of cash acquired	—			(202,044		)
Proceeds from escrow of Blacksmith acquisition	1,200			—
Net cash provided by (used in) investing activities	842			(198,327		)

Financing Activities
Proceeds from issuance of Senior Notes	—			100,250
Proceeds from issuance of Senior Term Loan	—			112,936
Payment of deferred financing costs	—			(648		)
Repayment of long-term debt	(58,000		)	(33,587		)
Proceeds from exercise of stock options	572			150
Shares surrendered as payment of tax withholding	(271		)	(264		)
Net cash (used in) provided by financing activities	(57,699		)	178,837

Effects of exchange rate changes on cash and cash equivalents	(31		)	—
(Decrease) increase in cash and cash equivalents	(8,895		)	42,169
Cash and cash equivalents - beginning of period	13,334			41,097

Cash and cash equivalents - end of period	$	4,439		$	83,266

Interest paid	$	28,503		$	13,354
Income taxes paid	$	12,699		$	4,096

See accompanying notes.

-4-

Prestige Brands Holdings, Inc.

Notes to Consolidated Financial Statements


1.	Business and Basis of Presentation

Nature of Business

Prestige Brands Holdings, Inc. (referred to herein as the “Company” or “we”, which reference shall, unless the context requires otherwise, be deemed to refer to Prestige Brands Holdings, Inc. and all of its direct and indirect wholly-owned subsidiaries on a consolidated basis) is engaged in the marketing, sales and distribution of Over-The-Counter (“OTC”) Healthcare and Household Cleaning brands to mass merchandisers, drug stores, supermarkets and dollar and club stores primarily in the United States, Canada and certain other international markets. Prestige Brands Holdings, Inc. is a holding company with no operations and is also the parent guarantor of the senior credit facility and the senior notes described in Note 10 to the Consolidated Financial Statements.

Basis of Presentation

The unaudited Consolidated Financial Statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. All significant intercompany transactions and balances have been eliminated in the Consolidated Financial Statements. In the opinion of management, the financial statements include all adjustments, consisting of normal recurring adjustments that are considered necessary for a fair presentation of our consolidated financial position, results of operations and cash flows for the interim periods presented. Our fiscal year ends on March 31st of each year. References in these Consolidated Financial Statements or notes to a year (e.g., “2012”) mean our fiscal year ending or ended on March 31st of that year. Operating results for the three and nine months ended December 31, 2011 are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2012. This financial information should be read in conjunction with our financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2011.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ from those estimates. As discussed below, our most significant estimates include those made in connection with the valuation of intangible assets, sales returns and allowances, trade promotional allowances and inventory obsolescence.

Cash and Cash Equivalents

We consider all short-term deposits and investments with original maturities of three months or less to be cash equivalents. Substantially all of our cash is held by a large regional bank with headquarters in California. We do not believe that, as a result of this concentration, we are subject to any unusual financial risk beyond the normal risk associated with commercial banking relationships.

Accounts Receivable

We extend non-interest-bearing trade credit to our customers in the ordinary course of business. We maintain an allowance for doubtful accounts receivable based upon historical collection experience and expected collectability of the accounts receivable. In an effort to reduce credit risk, we (i) have established credit limits for all of our customer relationships, (ii) perform ongoing credit evaluations of customers' financial condition, (iii) monitor the payment history and aging of customers' receivables, and (iv) monitor open orders against an individual customer's outstanding receivable balance.

Inventories

Inventories are stated at the lower of cost or market value, with cost determined by using the first-in, first-out method. We reduce inventories for diminution of value resulting from product obsolescence, damage or other issues affecting marketability, equal to the difference between the cost of the inventory and its estimated market value. Factors utilized in the determination of estimated market value include (i) current sales data and historical return rates, (ii) estimates of future demand, (iii) competitive pricing pressures, (iv) new product introductions, (v) product expiration dates, and (vi) component and packaging obsolescence.

-5-

Property and Equipment

Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives:



	Years
Machinery	5
Computer equipment	3
Furniture and fixtures	7

Leasehold improvements are amortized over the lesser of the term of the lease or five years.

Expenditures for maintenance and repairs are charged to expense as incurred. When an asset is sold or otherwise disposed of, we remove the cost and associated accumulated depreciation from the respective accounts and recognize the resulting gain or loss in the Consolidated Statements of Operations.

Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. An impairment loss is recognized if the carrying amount of the asset exceeds its fair value.

Goodwill

The excess of the purchase price over the fair market value of assets acquired and liabilities assumed in purchase business combinations is classified as goodwill. Goodwill is not amortized, although the carrying value is tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired. We test goodwill for impairment at the reporting unit “brand” level, which is one level below the operating segment level.

Intangible Assets

Intangible assets, which are comprised primarily of trademarks, are stated at cost less accumulated amortization. For intangible assets with finite lives, amortization is computed using the straight-line method over estimated useful lives ranging from 3 to 30 years.

Indefinite-lived intangible assets are tested for impairment at least annually in the fourth fiscal quarter of each year. Intangible assets with finite lives are reviewed for impairment whenever events or changes in circumstances indicate that their carrying amounts exceed their fair values and may not be recoverable. An impairment loss is recognized if the carrying amount of the asset exceeds its fair value.

Deferred Financing Costs

We have incurred debt origination costs in connection with the issuance of long-term debt. These costs are capitalized as deferred financing costs and amortized using the straight-line method, which approximates the effective interest method, over the term of the related debt.

Revenue Recognition

Revenues are recognized when the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) the selling price is fixed or determinable, (iii) the product has been shipped and the customer takes ownership and assumes the risk of loss, and (iv) collection of the resulting receivable is reasonably assured. We have determined that these criteria are met and the transfer of the risk of loss generally occurs when product is received by the customer, and, accordingly, we recognize revenue at that time. Provision is made for estimated discounts related to customer payment terms and estimated product returns at the time of sale based on our historical experience.

As is customary in the consumer products industry, we participate in the promotional programs of our customers to enhance the sale of our products. The cost of these promotional programs varies based on the actual number of units sold during a finite period of time. These promotional programs consist of direct-to-consumer incentives, such as coupons and temporary price reductions, as well as incentives to our customers, such as allowances for new distribution, including slotting fees, and cooperative advertising. Estimates of the costs of these promotional programs are based on (i) historical sales experience, (ii) the current promotional offering, (iii) forecasted data, (iv) current market conditions, and (v) communication with customer purchasing/marketing personnel. At the completion of a promotional program, the estimated amounts are adjusted to actual results.

Due to the nature of the consumer products industry, we are required to estimate future product returns. Accordingly, we record

-6-

an estimate of product returns concurrent with recording sales, which is made after analyzing (i) historical return rates, (ii) current economic trends, (iii) changes in customer demand, (iv) product acceptance, (v) seasonality of our product offerings, and (vi) the impact of changes in product formulation, packaging and advertising.

Cost of Sales

Cost of sales includes product costs, warehousing costs, inbound and outbound shipping costs, and handling and storage costs. Shipping, warehousing and handling costs for the three and nine months ended December 31, 2011 were $6.9 million and $20.1 million, respectively, and $6.6 million and $17.2 million, respectively, for the three and nine months ended December 31, 2010.

Advertising and Promotion Costs

Advertising and promotion costs are expensed as incurred. Allowances for new distribution costs associated with products, including slotting fees, are recognized as a reduction of sales. Under these new distribution arrangements, the retailers allow our products to be placed on the stores' shelves in exchange for such fees.

Stock-based Compensation

We recognize stock-based compensation by measuring the cost of services to be rendered based on the grant-date fair value of the equity award. Compensation expense is to be recognized over the period an employee is required to provide service in exchange for the award, generally referred to as the requisite service period.

Income Taxes

Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized.

The Income Taxes topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) prescribes a recognition threshold and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. As a result, we have applied a more-likely-than-not recognition threshold for all tax uncertainties. The guidance only allows the recognition of those tax benefits that have a greater than 50% likelihood of being sustained upon examination by the various taxing authorities.

We are subject to taxation in the United States and various state and foreign jurisdictions.

We classify penalties and interest related to unrecognized tax benefits as income tax expense in the Consolidated Statements of Operations.

Derivative Instruments

Companies are required to recognize derivative instruments as either assets or liabilities in the Consolidated Balance Sheets at fair value. The accounting for changes in the fair value of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and, further, on the type of hedging relationship. For those derivative instruments that are designated and qualify as hedging instruments, a company must designate the hedging instrument, based upon the exposure being hedged, as a fair value hedge, a cash flow hedge or a hedge of a net investment in a foreign operation.

While we have utilized derivative financial instruments in the past, we did not have any derivative financial instruments at December 31, 2011 or March 31, 2011, or for any of the periods presented.

Earnings Per Share

Basic earnings per share is calculated based on income available to common stockholders and the weighted-average number of shares outstanding during the reporting period. Diluted earnings per share is calculated based on income available to common stockholders and the weighted-average number of common and potential common shares outstanding during the reporting period. Potential common shares, composed of the incremental common shares issuable upon the exercise of stock options, stock appreciation rights and unvested restricted shares, are included in the earnings per share calculation to the extent that they are dilutive.

Recently Issued Accounting Standards

-7-

but consecutive statements. In both choices, an entity is required to present each component of net income along with total net income, each component of other comprehensive income along with a total for other comprehensive income, and a total amount for comprehensive income. This guidance eliminates the option to present the components of other comprehensive income as part of the statement of changes in stockholders' equity. This guidance does not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income.

In December 2011, the FASB issued guidance to defer the new requirement to present components of reclassifications of other comprehensive income on the face of the income statement. Based on this guidance, entities are still required to adopt either the single continuous statement or the two-statement approach required by the new guidance. However, entities should continue to report reclassifications out of accumulated other comprehensive income consistent with the requirements in effect before the adoption of the new standard (i.e., by component of other comprehensive income, either by displaying each component on a gross basis on the face of the appropriate financial statement or by displaying each component net of other changes on the face of the appropriate financial statement with the gross change disclosed in the notes). The new guidance and this deferral are effective for fiscal years, and interim periods within those years, beginning after December 15, 2011. Early adoption is permitted, but full retrospective application is required. The December 2011 deferral of the guidance issued in June 2011, as well as the June 2011 guidance, are effective at the same time. We do not expect that the adoption of this new guidance will have a material impact on our Consolidated Financial Statements.

In September 2011, the FASB issued guidance regarding testing goodwill for impairment. The new guidance is intended to simplify how entities test goodwill for impairment. The new guidance permits an entity to first assess qualitative factors to determine whether it is "more-likely-than-not" that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test described in the ASC Intangibles-Goodwill and Other topic. The more-likely-than-not threshold is defined as having a likelihood of more than 50%. The new guidance is effective for annual and interim goodwill impairment tests performed for fiscal years beginning after December 15, 2011. Early adoption is permitted. We do not expect that the adoption of this new guidance will have a material impact on our Consolidated Financial Statements.

In May 2011, the FASB issued guidance on fair value measurement. The ASC Fair Value Measurement topic amended the requirements for measuring fair value and for disclosing information about fair value measurements, including a consistent meaning of the term “fair value”. The new guidance states that the concepts of highest and best use and valuation premise are only relevant when measuring the fair value of non-financial assets (that is, it does not apply to financial assets or any liabilities). The disclosure requirements have been enhanced, with the most significant change requiring entities, for their recurring Level 3 fair value measurements, to disclose quantitative information about unobservable inputs used, a description of the valuation processes used by the entity, and a qualitative discussion about the sensitivity of the measurements. New disclosures are required about the use of a non-financial asset measured or disclosed at fair value if its use differs from its highest and best use. In addition, entities must report the level in the fair value hierarchy of assets and liabilities not recorded at fair value but where fair value is disclosed. This guidance is effective during interim and annual periods beginning after December 15, 2011 and is required to be applied prospectively. The adoption of this new guidance did not have a material impact on our Consolidated Financial Statements.

Management has reviewed and continues to monitor the actions of the various financial and regulatory reporting agencies and is currently not aware of any other pronouncement that could have a material impact on our consolidated financial position, results of operations or cash flows.


2.	Acquisitions

Blacksmith Acquisition

On November 1, 2010, we acquired 100% of the capital stock of Blacksmith Brands Holdings, Inc. (“Blacksmith”) for $190.0 million in cash, plus a working capital adjustment of $13.4 million, and we paid an additional $1.1 million on behalf of Blacksmith for the seller's transaction costs. As previously disclosed, we brought to arbitration a matter regarding the working capital adjustment related to Blacksmith. On July 20, 2011, we received notification from the arbitrator that we would be awarded a working capital adjustment pending final resolution and distribution from the escrow agent. In September 2011, we received $1.2 million in settlement of this matter, which reduced the amount of recorded goodwill related to Blacksmith.

In connection with this acquisition, we acquired five leading consumer OTC brands: Efferdent, Effergrip, PediaCare, Luden's, and NasalCrom. The purchase price was funded by cash provided by the issuance of long-term debt and additional bank borrowings, which are discussed further in Note 10 to the Consolidated Financial Statements.

The acquisition was accounted for in accordance with the Business Combinations topic of the ASC, which requires that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective

-8-

fair values at the date of acquisition.

The allocation of the purchase price to assets acquired and liabilities assumed is based on a valuation which we performed to determine the fair value of such assets as of the acquisition date. The following table summarizes our allocation of the $203.4 million purchase price to the assets acquired and liabilities assumed at the Blacksmith acquisition date:



(In thousands)	November 1, 2010

Cash acquired	$	2,507
Accounts receivable, net	17,473
Other receivables	1,198
Income taxes receivable	5
Inventories	22,155
Prepaids and other current assets	44
Property, plant and equipment, net	226
Goodwill	42,207
Trademarks	165,346
Other long-term assets	19
Total assets acquired	251,180

Accounts payable	7,060
Accrued expenses	5,212
Income taxes payable	2,031
Deferred income taxes	33,526
Total liabilities assumed	47,829

Total purchase price	$	203,351

We recorded goodwill based on the amount by which the purchase price exceeded the fair value of assets acquired and liabilities assumed. The amount of goodwill deductible for tax purposes is $4.6 million.

The fair value of the trademarks was comprised of $158.0 million of non-amortizable intangible assets and $7.3 million of amortizable intangible assets. We are amortizing the purchased amortizable intangible assets on a straight-line basis over an estimated weighted average useful life of 15 years. The weighted average remaining life for amortizable intangible assets at December 31, 2011 was 13.8 years.

The operating results of Blacksmith have been included in our Consolidated Financial Statements from November 1, 2010, the date of acquisition. Revenues of the acquired operations for the three and nine months ended December 31, 2011 were $28.4 million and $70.0 million, respectively.

The following table provides our unaudited pro forma revenues, income from continuing operations and income from continuing operations per basic and diluted common share as if the results of Blacksmith's operations had been included in our operations commencing on April 1, 2010, and based upon available information related to Blacksmith's operations. This pro forma information is not necessarily indicative either of the combined results of operations that actually would have been realized by us had the Blacksmith acquisition been consummated at the beginning of the period for which the pro forma information is presented, or of future results.



(In thousands, except per share data)	Three Months Ended December 31, 2010		Nine Months Ended December 31, 2010

Revenues	$	98,564	$	295,838
Income from continuing operations	2,470		25,033

Basic earnings per share:
Income from continuing operations	$	0.05	$	0.50

Diluted earnings per share:
Income from continuing operations	$	0.05	$	0.50

-9-

Dramamine Acquisition

On January 6, 2011, we acquired certain assets comprising the Dramamine brand in the United States. The purchase price was $77.1 million in cash, after a $0.1 million post-closing inventory adjustment and including transaction costs of $1.2 million incurred in the acquisition. The purchase price was funded by cash on hand.

The acquisition was accounted for in accordance with the Business Combinations topic of the ASC. Accordingly, as the Dramamine assets acquired do not constitute a business, as defined in the ASC, we have accounted for the transaction as an asset acquisition. The total consideration paid, including transaction costs, has been allocated to the tangible and intangible assets acquired based upon their relative fair values at the date of acquisition.

The allocation of the purchase price to assets acquired and liabilities assumed is based on valuations which we performed to determine the fair value of such assets as of the acquisition date. The following table summarizes our allocation of the $77.1 million purchase price to the assets we acquired comprising the Dramamine brand:



(In thousands)	January 6, 2011

Inventories	$	1,249
Trademark	75,866
Total purchase price	$	77,115

The $75.9 million fair value of the acquired Dramamine trademark was comprised solely of non-amortizable intangible assets.

Acquisition of GlaxoSmithKline OTC Brands


3.	Discontinued Operations and Sale of Certain Assets

On September 1, 2010, we sold certain assets related to the Cutex nail polish remover brand for $4.1 million. In accordance with the Discontinued Operations topic of the ASC, we reclassified the related operating results as discontinued operations in our Consolidated Financial Statements and related notes for all periods presented. We recognized a loss of $0.9 million on a pre-tax basis and $0.6 million, net of tax effects of $0.3 million, on the sale in the second quarter of 2011. As a result of the divestiture of Cutex, which comprised a substantial majority of the assets in our previously reported Personal Care segment, we reclassified the then remaining Personal Care segment assets to the OTC Healthcare segment for all periods presented.

The following table summarizes the results of discontinued operations:



(In thousands)	Three Months Ended December 31,				Nine Months Ended December 31,
	2011		2010		2011		2010
Components of Income
Revenues	$	—	$	84	$	—	$	4,027
Income from discontinued operations, net of income tax	—		32		—		591

-10-


4.	Accounts Receivable

Accounts receivable consist of the following:



(In thousands)	December 31, 2011			March 31, 2011
Components of Accounts Receivable
Trade accounts receivable	$	54,770		$	50,333
Other receivables	607			712
	55,377			51,045
Less allowances for discounts, returns and uncollectible accounts	(5,214		)	(6,652		)
Accounts receivable, net	$	50,163		$	44,393


5.	Inventories

Inventories consist of the following:



(In thousands)	December 31, 2011		March 31, 2011
Components of Inventories
Packaging and raw materials	$	797	$	1,287
Finished goods	42,782		38,464
Inventories	$	43,579	$	39,751

Inventories are carried and depicted above at the lower of cost or market, which includes a reduction in inventory values of $2.1 million and $0.6 million at December 31, 2011 and March 31, 2011, respectively, related to obsolete and slow-moving inventory.


6.	Property and Equipment

Property and equipment consist of the following:



(In thousands)	December 31, 2011			March 31, 2011
Components of Property and Equipment
Machinery	$	1,431		$	1,215
Computer equipment	2,471			2,341
Furniture and fixtures	241			239
Leasehold improvements	431			423
	4,574			4,218
Accumulated depreciation	(3,336		)	(2,774		)
Property and equipment, net	$	1,238		$	1,444

We recorded depreciation expense of $0.2 million for each of the three months ended December 31, 2011 and December 31, 2010, and of $0.6 million and $0.5 million for the nine months ended December 31, 2011 and December 31, 2010, respectively.

-11-


7.	Goodwill

A reconciliation of the activity affecting goodwill by operating segment is as follows:



(In thousands)	OTC Healthcare			Household Cleaning			Consolidated

Balance — March 31, 2011
Goodwill	$	277,986		$	72,549		$	350,535
Accumulated impairment losses	(130,479		)	(65,160		)	(195,639		)
	147,507			7,389			154,896

Additions	—			—			—

Balance — December 31, 2011
Goodwill	277,986			72,549			350,535
Blacksmith escrow settlement *	(1,200		)	—			(1,200		)
Accumulated impairment losses	(130,479		)	(65,160		)	(195,639		)
	$	146,307		$	7,389		$	153,696

* As previously disclosed, we brought to arbitration a matter regarding the working capital adjustment related to Blacksmith. On July 20, 2011, we received notification from the arbitrator that we would be awarded a working capital adjustment pending final resolution and distribution from the escrow agent. In September 2011, we received $1.2 million in settlement of this matter, which reduced the amount of recorded goodwill related to Blacksmith.

At March 31, 2011, during our annual test for goodwill impairment, there were no indicators of impairment under the analysis. Accordingly, no impairment charge was recorded in 2011. Additionally, for the three and nine months ended December 31, 2011, no indicators of impairment existed and no impairment charge was recorded.

The discounted cash flow methodology is a widely-accepted valuation technique to estimate fair value utilized by market participants in the transaction evaluation process and has been applied consistently. We also considered our market capitalization at March 31, 2011, as compared to the aggregate fair values of our reporting units, to assess the reasonableness of our estimates pursuant to the discounted cash flow methodology. The estimates and assumptions made in assessing the fair value of our reporting units and the valuation of the underlying assets and liabilities are inherently subject to significant uncertainties. Consequently, changing rates of interest and inflation, declining sales or margins, increases in competition, changing consumer preferences, technical advances, or reductions in advertising and promotion may require impairments in the future.

As discussed in Note 1, in accordance with recent guidance from the FASB, an entity is permitted to first assess qualitative factors in testing goodwill for impairment prior to performing a quantitative assessment. The new guidance is effective for annual and interim goodwill impairment tests performed for fiscal years beginning after December 15, 2011. This new guidance will be effective for the Company in fiscal year 2013.

-12-


8.	Intangible Assets

A reconciliation of the activity affecting intangible assets is as follows:



(In thousands)	Indefinite Lived Trademarks		Finite Lived Trademarks		Non Compete Agreement		Totals
Carrying Amounts
Balance — March 31, 2011	$	688,484	$	150,293	$	158	$	838,935
Additions	—		—		—		—
Balance — December 31, 2011	$	688,484	$	150,293	$	158	$	838,935

Accumulated Amortization
Balance — March 31, 2011	$	—	$	52,416	$	158	$	52,574
Additions	—		7,119		—		7,119
Balance — December 31, 2011	$	—	$	59,535	$	158	$	59,693

Intangible assets, net — December 31, 2011	$	688,484	$	90,758	$	—	$	779,242

In a manner similar to goodwill, we completed our test for impairment of our indefinite-lived intangible assets during the three months ended March 31, 2011. We did not record an impairment charge, as facts and circumstances indicated that the fair values of the intangible assets for our operating segments exceeded their carrying values. Additionally, for the indefinite-lived intangible assets, an evaluation of the facts and circumstances as of December 31, 2011 continues to support an indefinite useful life for these assets. Therefore, no impairment charge was recorded for the three and nine months ended December 31, 2011.

The weighted average remaining life for finite-lived intangible assets at December 31, 2011 was approximately 14.1 years and the amortization expense for the three and nine months ended December 31, 2011 was $2.4 million and $7.1 million, respectively. At December 31, 2011, intangible assets are expected to be amortized over a period of 3 to 30 years as follows:



(In thousands)
Year Ending March 31,	Amount
2012 (Remaining three months ending March 31, 2012)	$	2,285
2013	8,552
2014	7,416
2015	6,082
2016	6,082
Thereafter	60,341
	$	90,758


9.	Other Accrued Liabilities

Other accrued liabilities consist of the following:



(In thousands)	December 31, 2011		March 31, 2011

Accrued marketing costs	$	11,458	$	9,967
Accrued payroll	5,035		7,589
Accrued commissions	513		408
Accrued income taxes	5		531
Accrued professional fees	6,326		1,953
Accrued severance	198		1,324
Accrued other	370		508
	$	23,905	$	22,280

-13-


10.	Long-Term Debt

Long-term debt consists of the following, as of the dates indicated:



(In thousands, except percentages)	December 31, 2011			March 31, 2011
Senior secured term loan facility (“2010 Senior Term Loan”) that bears interest at the Company's option at either the prime rate plus a margin of 2.25% or LIBOR plus 3.25% with a LIBOR floor of 1.5%. At December 31, 2011, the average interest rate on the 2010 Senior Term Loan was 4.75%. All required principal payments prior to maturity have been paid and the remaining principal on the 2010 Senior Term Loan is due on the maturity date. The 2010 Senior Term Loan matures on March 24, 2016 and is collateralized by substantially all of the Company's assets. The 2010 Senior Term Loan is unconditionally guaranteed by Prestige Brands Holdings, Inc. and its domestic wholly-owned subsidiaries, other than Prestige Brands, Inc. (the "Borrower"). Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries.	$	184,000		$	242,000

Senior unsecured notes ("2010 Senior Notes") bear interest at 8.25%, with interest only payable on April 1st and October 1st of each year. The 2010 Senior Notes mature on April 1, 2018; however, the Company may earlier redeem some or all of the 2010 Senior Notes at redemption prices set forth in the indenture governing the 2010 Senior Notes (the "Senior Notes Indenture"). The 2010 Senior Notes are unconditionally guaranteed by Prestige Brands Holdings, Inc. and its domestic wholly-owned subsidiaries other than Prestige Brands, Inc., the issuer. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries.	250,000			250,000
	434,000			492,000
Current portion of long-term debt	—			—
	434,000			492,000
Less: unamortized discount on the 2010 Senior Notes	(4,368		)	(5,055		)
Long-term debt, net of unamortized discount and premium	$	429,632		$	486,945

On March 24, 2010, Prestige Brands, Inc. issued $150.0 million of 2010 Senior Notes, with an interest rate of 8.25% and a maturity date of April 1, 2018. On November 1, 2010, Prestige Brands, Inc. issued an additional $100.0 million of the 2010 Senior Notes. The 2010 Senior Notes issued in March and November 2010 were issued at an aggregate face value of $150.0 million and $100.0 million, respectively, with a discount to the initial purchasers of $2.2 million and a premium of $0.3 million, respectively, and net proceeds to the Company of $147.8 million and $100.3 million, respectively, yielding an 8.5% effective interest rate for the 2010 Senior Notes on a combined basis.

On March 24, 2010, Prestige Brands, Inc. entered into the 2010 Senior Term Loan for $150.0 million, with an interest rate at LIBOR plus 3.25% with a LIBOR floor of 1.5% and a maturity date of March 24, 2016. The $150.0 million 2010 Senior Term Loan was entered into with a discount to lenders of $1.8 million and net proceeds to the Company of $148.2 million, yielding a 5.0% effective interest rate. On November 1, 2010, we, together with the Borrower and certain of our other subsidiaries, executed an Increase Joinder to our Credit Agreement dated March 24, 2010 (the "Increase Joinder"), pursuant to which the Borrower entered into an incremental term loan in the amount of $115.0 million. The incremental 2010 Senior Term Loan will also mature on March 24, 2016.

Additionally, on March 24, 2010, Prestige Brands, Inc. entered into a non-amortizing senior secured revolving credit facility (“2010 Revolving Credit Facility” and, collectively with the 2010 Senior Term Loan, the “Credit Agreement”) in an aggregate principal amount of up to $30.0 million. On November 1, 2010, pursuant to the Increase Joinder, the amount of the 2010 Revolving Credit Facility was increased by $10.0 million and the Borrower had borrowing capacity under the 2010 Revolving Credit Facility in an aggregate principal amount of up to $40.0 million. Our 2010 Revolving Credit Facility was available for maximum borrowings of $40.0 million at December 31, 2011. Except for the increase in the amount of the 2010 Revolving Credit Facility, no other changes were made to the 2010 Revolving Credit Facility.

In connection with the financing activities of March 2010 relating to the 2010 Senior Notes, the 2010 Senior Term Loan and the 2010 Revolving Credit Facility, we incurred $7.3 million in issuance costs, of which $6.6 million was capitalized as deferred financing costs and $0.7 million was expensed. In connection with the financing activities of November 2010 relating to the 2010 Senior Notes, the 2010 Senior Term Loan and the 2010 Revolving Credit Facility, we incurred $0.6 million in issuance costs, all of which were capitalized as deferred financing costs. The deferred financing costs are being amortized over the terms of the

-14-

related loan and notes.

On March 24, 2010, we retired our existing Senior Secured Term Loan Facility with an original maturity date of April 6, 2011. In addition, on March 24, 2010, we repaid a portion and, on April 15, 2010, redeemed in full the remaining outstanding indebtedness under our previously outstanding Senior Subordinated Notes due in 2012, which bore interest at 9.25% with a maturity date of April 15, 2012. In connection with the refinancing, we recognized a $0.3 million loss on the extinguishment of debt for the nine months ended December 31, 2010.

The 2010 Senior Notes are senior unsecured obligations of the Company and are guaranteed on a senior unsecured basis. The 2010 Senior Notes are effectively junior in right of payment to all existing and future secured obligations of the Company, equal in right of payment with all existing and future senior unsecured indebtedness of the Company, and senior in right of payment to all future subordinated debt of the Company.

At any time prior to April 1, 2014, we may redeem the 2010 Senior Notes in whole or in part at a redemption price equal to 100% of the principal amount of the notes redeemed, plus a “make-whole premium” calculated as set forth in the Senior Notes Indenture, together with accrued and unpaid interest, if any, to the date of redemption. We may redeem the 2010 Senior Notes in whole or in part at any time on or after the 12-month period beginning April 1, 2014 at a redemption price of 104.125% of the principal amount thereof, at a redemption price of 102.063% of the principal amount thereof if the redemption occurs during the 12-month period beginning on April 1, 2015, and at a redemption price of 100% of the principal amount thereof if the redemption occurs on and after April 1, 2016, in each case, plus accrued and unpaid interest, if any, to the redemption date. In addition, prior to April 1, 2013, with the net cash proceeds from certain equity offerings, we may redeem up to 35% in aggregate principal amount of the 2010 Senior Notes at a redemption price of 108.250% of the principal amount of the 2010 Senior Notes to be redeemed, plus accrued and unpaid interest, if any, to the redemption date.

The Credit Agreement contains various financial covenants, including provisions that require us to maintain certain leverage and interest coverage ratios and not to exceed annual capital expenditures of $3.0 million. The Credit Agreement and the Senior Notes Indenture also contain provisions that restrict us from undertaking specified corporate actions, such as asset dispositions, acquisitions, dividend payments, repurchases of common shares outstanding, changes of control, incurrences of indebtedness, creation of liens, making of loans and transactions with affiliates. Additionally, the Credit Agreement and the Senior Notes Indenture contain cross-default provisions whereby a default pursuant to the terms and conditions of certain indebtedness will cause a default on the remaining indebtedness under the Credit Agreement and the Senior Notes Indenture. At December 31, 2011, we were in compliance with the covenants under our long-term indebtedness.

During the nine months ended December 31, 2011, we made voluntary principal payments against outstanding indebtedness of $58.0 million in excess of required payments under the Credit Agreement governing the 2010 Senior Term Loan. In accordance with the Credit Agreement governing the 2010 Senior Term Loan, such payments were applied against the first four required principal payments, and any additional principal payments are applied ratably toward the remaining required principal payments. As such, we do not have a required principal payment until the 2010 Senior Term Loan matures in 2016.

Future principal payments required in accordance with the terms of the Credit Agreement and the Senior Notes Indenture are as follows:



(In thousands)
Year Ending March 31,	Amount
2012 (Remaining three months ending March 31, 2012)	$	—
2013	—
2014	—
2015	—
2016	184,000
2017	—
Thereafter	250,000
	$	434,000

On December 20, 2011, we entered into two separate agreements with GSK to acquire a total of 17 North American OTC pharmaceutical brands for $660.0 million in cash. On January 31, 2012, we completed the acquisition of 15 of these brands for $615.0 million. The acquisition of the remaining two brands is expected to be completed no later than June 30, 2012. The acquisition and the related financing are more fully described in Note 22- Subsequent Events.

-15-


11.	Fair Value Measurements

As we deem appropriate, we may from time to time utilize derivative financial instruments to mitigate the impact of changing interest rates associated with our long-term debt obligations or other derivative financial instruments. While we have utilized derivative financial instruments in the past, we did not have any derivative financial instruments outstanding at either December 31, 2011 or at March 31, 2011 or during any of the periods presented. We have not entered into derivative financial instruments for trading purposes; all of our derivatives were over-the-counter instruments with liquid markets.

For certain of our financial instruments, including cash, accounts receivable, accounts payable and other current liabilities, the carrying amounts approximate their respective fair values due to the relatively short maturity of these amounts.

At December 31, 2011 and March 31, 2011, the carrying value of the 2010 Senior Term Loan was $184.0 million and $242.0 million, respectively. The terms of the 2010 Senior Term Loan provide that the interest rate is adjusted, at our option, on either a monthly or quarterly basis, to the prime rate plus a margin of 2.25% or to LIBOR, with a floor of 1.50%, plus a margin of 3.25%. The market value of our 2010 Senior Term Loan was approximately $183.5 million and $243.4 million at December 31, 2011 and March 31, 2011, respectively.

At December 31, 2011 and March 31, 2011, the carrying value of our 2010 Senior Notes was $250.0 million. The market value of these notes was approximately $258.8 million and $264.4 million at December 31, 2011 and March 31, 2011, respectively. The market values have been determined from market transactions in our debt securities.


12.	Stockholders' Equity

The Company is authorized to issue 250.0 million shares of common stock, $0.01 par value per share, and 5.0 million shares of preferred stock, $0.01 par value per share. The Board of Directors may direct the issuance of the undesignated preferred stock in one or more series and determine preferences, privileges and restrictions thereof.

Each share of common stock has the right to one vote on all matters submitted to a vote of stockholders. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors, subject to prior rights of holders of all classes of stock outstanding having priority rights as to dividends. No dividends have been declared or paid on the Company's common stock through December 31, 2011.

During the three and nine months ended December 31, 2011, we repurchased zero and 20,999 shares, respectively, of restricted common stock from our employees pursuant to the provisions of the various employee restricted stock awards. The repurchases were at an average price of $12.86. During the three and nine months ended December 31, 2010, we repurchased 17,719 and 36,032 shares, respectively, of restricted common stock from our employees pursuant to the provisions of the various employee restricted stock awards. The repurchases were at an average price of $12.07 and $13.68, respectively, during the three and nine months ended December 31, 2010. All of the repurchased shares have been recorded as treasury stock.


13.	Accumulated Other Comprehensive Income (Loss)

Accumulated other comprehensive income (loss) (“AOCI”) is comprised of various items that affect equity and results from recognized transactions and other economic events, other than transactions with owners in their capacity as owners. AOCI consisted of the following at December 31, 2011 and March 31, 2011:



	December 31,			March 31,
(In thousands)	2011			2011
Components of Accumulated Other Comprehensive Loss
Cumulative translation adjustment	$	(70	)	$	—
Total accumulated other comprehensive loss	$	(70	)	$	—

-16-

The following table describes the components of comprehensive income for the nine months ended December 31, 2011 and 2010:



	Nine Months Ended December 31,
(In thousands)	2011			2010
Components of Comprehensive Income
Net income	$	37,227		$	22,806
Translation adjustments, net of related income tax effects	(70		)	—
Comprehensive Income	$	37,157		$	22,806


14.	Earnings Per Share

Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is computed based on the weighted-average number of shares of common stock outstanding plus the effect of potentially dilutive common shares outstanding during the period using the treasury stock method, which includes stock options, restricted stock awards and restricted stock units. The following table sets forth the computation of basic and diluted earnings per share:



	Three Months Ended December 31,				Nine Months Ended December 31,
(In thousands, except per share data)	2011		2010		2011		2010
Numerator
Income from continuing operations	$	9,510	$	2,146	$	37,227	$	22,765
Income from discontinued operations and loss on sale of discontinued operations, net of income tax	—		32		—		41
Net income	$	9,510	$	2,178	$	37,227	$	22,806

Denominator
Denominator for basic earnings per share — weighted average shares	50,307		50,085		50,256		50,059
Dilutive effect of unvested restricted common stock (including restricted stock units) and options issued to employees and directors	377		448		411		201
Denominator for diluted earnings per share	50,684		50,533		50,667		50,260

Earnings per Common Share:
Basic earnings per share from continuing operations	$	0.19	$	0.04	$	0.74	$	0.46
Basic earnings per share from discontinued operations and loss on sale of discontinued operations	—		—		—		—
Basic net earnings per share	$	0.19	$	0.04	$	0.74	$	0.46

Diluted earnings per share from continuing operations	$	0.19	$	0.04	$	0.73	$	0.45
Diluted earnings per share from discontinued operations and loss on sale of discontinued operations	—		—		—		—
Diluted net earnings per share	$	0.19	$	0.04	$	0.73	$	0.45

At December 31, 2011 and December 31, 2010, there were zero and 0.1 million shares, respectively, of restricted stock awards that have been excluded from the calculation of basic earnings per share as these awards were subject to contingencies that were not met as of the end of each respective period. Additionally, for the three months ended December 31, 2011 and 2010, there were 0.7 million and 0.2 million shares, respectively, attributable to outstanding stock-based awards that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive. For the nine months ended December 31, 2011 and 2010, there were 0.5 million and 0.1 million shares, respectively, attributable to outstanding stock-based awards that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive.

-17-


15.	Share-Based Compensation

In connection with our initial public offering, the Board of Directors adopted the 2005 Long-Term Equity Incentive Plan (the “Plan”), which provides for the grant of up to a maximum of 5.0 million shares of restricted stock, stock options, restricted stock units and other equity-based awards. Directors, officers and other employees of the Company and its subsidiaries, as well as others performing services for the Company, are eligible for grants under the Plan.

During the three and nine months ended December 31, 2011, pre-tax share-based compensation costs charged against income were $0.7 million and $2.4 million, respectively, and the related income tax benefit recognized was $0.2 million and $0.6 million, respectively. During the three and nine months ended December 31, 2010, pre-tax share-based compensation costs charged against income were $1.1 million and $2.8 million, respectively, and the related income tax benefit recognized was $0.4 million and $1.1 million, respectively.

Restricted Shares

Restricted shares granted to employees under the Plan generally vest in three to five years, contingent on attainment of certain performance goals by the Company, including revenue and earnings before income taxes, depreciation and amortization targets, or the attainment of certain time vesting thresholds. The restricted share awards provide for accelerated vesting if there is a change of control, as defined in the Plan. On May 10, 2011, the Compensation Committee of the Board of Directors granted 89,923 shares of restricted common stock to certain executive officers and employees under the Plan at a grant-date fair value of $11.27 per share. These restricted common stock awards will vest in their entirety three years after the date of grant so long as the grantee remains employed by us. In addition, on May 30, 2011, previously issued restricted performance shares vested, resulting in the issuance of 16,153 additional shares pursuant to such equity grants at a fair value of $10.91 per share. On August 2, 2011, the Compensation Committee of our Board of Directors granted 16,408 shares of restricted stock units to the independent members of our Board of Directors. The restricted stock units will vest in their entirety one year after the date of grant so long as membership on the Board of Directors continues through the vesting date, with settlement in common stock to occur on the earliest of the director's death, disability or six month anniversary of the date on which the director's Board membership ceases for reasons other than death or disability. The fair value of restricted shares is determined using the closing price of our common stock on the day preceding the grant date. The weighted-average grant-date fair value of restricted shares granted during the nine months ended December 31, 2011 and 2010 was $11.35 and $9.01, respectively.

A summary of the Company's restricted shares granted under the Plan is presented below:



Restricted Shares	Shares (in thousands)		Weighted- Average Grant-Date Fair Value
Nine months ended December 31, 2010:
Nonvested at March 31, 2010	287.1		$	8.86
Granted	122.6		9.01
Vested and issued	(88.0	)	9.50
Forfeited	(42.5	)	10.09
Outstanding at December 31, 2010	279.2		8.54
Vested at December 31, 2010	29.2		6.84


Nine months ended December 31, 2011:
Nonvested at March 31, 2011	275.4		8.46
Granted	122.5		11.35
Vested and issued	(103.4	)	9.93
Forfeited	(15.2	)	10.72
Outstanding at December 31, 2011	279.3		9.06
Vested at December 31, 2011	54.0		7.40

Options

The Plan provides that the exercise price of options granted shall be no less than the fair market value of the Company's common stock on the date the options are granted. Options granted have a term of no greater than 10 years from the date of grant and vest in accordance with a schedule determined at the time the option is granted, generally three to five years. The option awards provide

-18-

for accelerated vesting if there is a change in control, as defined in the Plan.

The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model that uses the assumptions noted in the table below. Expected volatilities are based on the historical volatility of our common stock and other factors, including the historical volatilities of comparable companies. We use appropriate historical data, as well as current data, to estimate option exercise and employee termination behaviors. Employees that are expected to exhibit similar exercise or termination behaviors are grouped together for the purposes of valuation. The expected terms of the options granted are derived from management's estimates and consideration of information derived from the public filings of companies similar to us and represent the period of time that options granted are expected to be outstanding. The risk-free rate represents the yield on U.S. Treasury bonds with a maturity equal to the expected term of the granted option. On May 10, 2011, the Compensation Committee of the Board of Directors granted stock options to acquire 308,154 shares of common stock to certain executive officers and employees under the Plan at an exercise price of $11.27 per share.

The weighted-average grant-date fair value of the options granted during the nine months ended December 31, 2011 and 2010 was $5.83 and $4.91, respectively.



	Nine Months Ended December 31,
	2011			2010
Expected volatility	53.0		%	52.8		%
Expected dividends	$	—		$	—
Expected term in years	6.5			7.0
Risk-free rate	2.4		%	3.2		%

A summary of option activity under the Plan is as follows:



Options	Shares (in thousands)		Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term	Aggregate Intrinsic Value (in thousands)
Nine months ended December 31, 2010:
Outstanding at March 31, 2010	1,584.2		$	8.50
Granted	418.5		9.26
Exercised	(13.7	)	10.91
Forfeited or expired	(301.0	)	10.63
Outstanding at December 31, 2010	1,688.0		8.29		7.9	$	6,294.3
Exercisable at December 31, 2010	495.8		9.60		5.9	1,280.1

Nine months ended December 31, 2011:
Outstanding at March 31, 2011	1,621.5		8.19
Granted	308.1		11.27
Exercised	(54.2	)	10.54
Forfeited or expired	(78.9	)	11.93
Outstanding at December 31, 2011	1,796.5		8.48		7.9	5,124.5
Exercisable at December 31, 2011	678.0		8.43		7.4	2,035.1

The aggregate intrinsic value of options exercised in the nine months ended December 31, 2011 was $0.1 million. The aggregate intrinsic value at December 31, 2011 for options granted during the nine months ended December 31, 2011 was zero.

At December 31, 2011, there were $3.4 million of unrecognized compensation costs related to nonvested share-based compensation arrangements under the Plan, based on management's estimate of the shares that will ultimately vest. We expect to recognize such costs over a weighted-average period of 1.0 years. The total fair value of shares vested during the nine months ended December 31, 2011 and 2010 was $2.8 million and $0.8 million, respectively. For the nine months ended December 31, 2011, cash received

-19-

from the exercise of stock options was $0.7 million, and we realized $0.1 million in tax benefits for the tax deductions resulting from these option exercises. There were 13,700 stock options exercised by a former employee at a weighted average exercise price of $10.91 during the nine months ended December 31, 2010. At December 31, 2011, there were 2.5 million shares available for issuance under the Plan.


16.	Income Taxes

Income taxes are recorded in our quarterly financial statements based on our estimated annual effective income tax rate, subject to adjustments for discrete events should they occur. The effective tax rate used in the calculation of income taxes was 38.7% and 59.9%, respectively, for the three months ended December 31, 2011 and December 31, 2010. The effective tax rate used in the calculation of income taxes was 38.3% and 41.2%, respectively, for the nine months ended December 31, 2011 and December 31, 2010. The decrease in the effective tax rate for the three and nine months ended December 31, 2011 is primarily due to $0.8 million of non-deductible transaction expenses related to the Blacksmith acquisition and a $0.3 million charge for our deferred state tax rate incurred in the prior year period.

At December 31, 2011, a wholly-owned subsidiary had a net operating loss carryforward of approximately $1.5 million which may be used to offset future taxable income of the consolidated group and which begins to expire in 2020. The net operating loss carryforward is subject to an annual limitation as to usage of approximately $0.2 million pursuant to Internal Revenue Code Section 382.

Uncertain tax liability activity is as follows:



(In thousands)	2011			2010
Balance — March 31	$	456		$	315
Adjustments based on tax positions related to the current year	(164		)	141
Balance — December 31	$	292		$	456

We recognize interest and penalties related to uncertain tax positions as a component of income tax expense. We did not incur any material interest or penalties related to income taxes in any of the periods presented. We do not anticipate any significant events or circumstances that would cause a material change to these uncertainties during the ensuing year.


17.	Commitments and Contingencies

Trutek Arbitration

On November 1, 2010, Trutek Corp. (“Trutek”) commenced an arbitration proceeding against Prestige Brands, Inc. (“Prestige Brands”), a wholly-owned subsidiary of the Company, in which Trutek alleged that Prestige Brands breached certain terms of a license agreement between Trutek and Prestige Brands providing for the license of certain intellectual property by Trutek to Prestige Brands for an allergy relief product. Prestige Brands denied Trutek's allegations of breach of the license agreement. The arbitration hearing was conducted in October 2011 and closing arguments were made on November 30, 2011. We received a written decision from the arbitration panel on January 30, 2012 in which the panel denied all of Trutek's claims in the arbitration.

In addition to the matters described above, we are involved from time to time in other routine legal matters and other claims incidental to our business. We review outstanding claims and proceedings internally and with external counsel as necessary to assess probability and amount of potential loss. These assessments are re-evaluated at each reporting period and as new information becomes available to determine whether a reserve should be established or if any existing reserve should be adjusted. The actual cost of resolving a claim or proceeding ultimately may be substantially different than the amount of the recorded reserve. In addition, because it is not permissible under GAAP to establish a litigation reserve until the loss is both probable and estimable, in some cases there may be insufficient time to establish a reserve prior to the actual incurrence of the loss (upon verdict and judgment at trial, for example, or in the case of a quickly negotiated settlement). We believe the resolution of routine matters and other incidental claims, taking into account reserves and insurance, will not have a material adverse effect on our business, financial condition or results from operations.

Lease Commitments

We have operating leases for office facilities and equipment in New York and Wyoming, which expire at various dates through 2014.

-20-

The following summarizes future minimum lease payments for our operating leases as of December 31, 2011:



(In thousands)	Facilities		Equipment		Total
Year Ending March 31,
2012 (Remaining three months ending March 31, 2012)	$	261	$	23	$	284
2013	1,082		50		1,132
2014	719		23		742
2015	56		—		56
Thereafter	—		—		—
	$	2,118	$	96	$	2,214

Rent expense for the three months ended December 31, 2011 and 2010 was $0.3 million and $0.2 million, respectively, while rent expense for the nine months ended December 30, 2011 and 2010 was $0.7 million and $0.6 million, respectively.

Purchase Commitments

We have entered into a ten year supply agreement for the exclusive manufacture of a portion of one of our Household Cleaning products. Although we are committed under the supply agreement to pay the minimum amounts set forth in the table below, the total commitment is less than ten percent of the estimated purchases that we expect to make during the course of the agreement.



(In thousands)
Year Ending March 31,	Amount
2012 (Remaining three months ending March 31, 2012)	$	296
2013	1,166
2014	1,136
2015	1,105
2016	1,074
Thereafter	3,599
	$	8,376


18.	Concentrations of Risk

Our revenues are concentrated in the areas of OTC Healthcare and Household Cleaning products. We sell our products to mass merchandisers, food and drug stores, and dollar and club stores. During the three and nine months ended December 31, 2011, approximately 55.0% and 54.8%, respectively, of our total revenues were derived from our five top selling brands. During the three and nine months ended December 31, 2010, approximately 61.5% and 68.6%, respectively, of our total revenues were derived from our five top selling brands. One customer accounted for more than 10% of our gross revenues for each of the periods presented. Such customer accounted for approximately 20.9% and 19.1% of our gross revenues for the three and nine months ended December 31, 2011, respectively, and 22.8% and 22.6% of our gross revenues for the three and nine months ended December 31, 2010, respectively. At December 31, 2011, approximately 23.4% of accounts receivable were owed by the same customer.

We manage product distribution in the continental United States through a third-party distribution center in St. Louis, Missouri. A serious disruption, such as a flood or fire, to the main distribution center could damage our inventories and could materially impair our ability to distribute our products to customers in a timely manner or at a reasonable cost. We could incur significantly higher costs and experience longer lead times associated with the distribution of our products to our customers during the time that it takes us to reopen or replace our distribution center. As a result, any such disruption could have a material adverse effect on our sales and profitability.

At December 31, 2011, we had relationships with 52 third-party manufacturers. Of those, we had long-term contracts with 15 manufacturers that produced items that accounted for approximately 66.7% of gross sales for the nine months ended December 31, 2011. At December 31, 2010, we had relationships with 43 third-party manufacturers. Of those, we had long-term contracts with eight manufacturers that produced items that accounted for approximately 43.5% of gross sales for the nine months ended December 31, 2010. The fact that we do not have long-term contracts with certain manufacturers means they could cease producing products at any time and for any reason, or initiate arbitrary and costly price increases, which could have a material adverse effect on our business, financial condition and results from operations.

-21-


19.	Business Segments

Segment information has been prepared in accordance with the Segment Reporting topic of the FASB ASC. As described in Note 3, on September 1, 2010, we sold certain assets related to the Cutex nail polish remover brand included in our previously reported Personal Care segment to an unrelated third party. The assets sold comprised a substantial majority of the assets in our previously reported Personal Care segment. The remaining assets and revenues generated do not constitute a reportable segment under the Segment Reporting topic of the FASB ASC. Therefore, we reclassified the remaining assets and results of the Personal Care segment to the OTC Healthcare segment for all periods presented. Our current operating and reportable segments now consist of (i) OTC Healthcare and (ii) Household Cleaning.

There were no inter-segment sales or transfers during any of the periods presented. We evaluate the performance of our operating segments and allocate resources to them based primarily on contribution margin.

The tables below summarize information about our operating and reportable segments.



	Three Months Ended December 31, 2011
(In thousands)	OTC Healthcare		Household Cleaning		Consolidated
Net sales	$	84,711	$	21,088	$	105,799
Other revenues	195		256		451
Total revenues	84,906		21,344		106,250
Cost of sales	35,329		15,799		51,128
Gross profit	49,577		5,545		55,122
Advertising and promotion	14,170		1,104		15,274
Contribution margin	$	35,407	$	4,441	39,848
Other operating expenses					16,218
Operating income					23,630
Other expense					8,116
Provision for income taxes					6,004
Income from continuing operations					9,510
Income from discontinued operations, net of income tax					—
Loss on sale of discontinued operations, net of income tax					—
Net income					$	9,510



	Three Months Ended December 31, 2010
(In thousands)	OTC Healthcare		Household Cleaning		Consolidated
Net sales	$	67,287	$	22,790	$	90,077
Other revenues	173		358		531
Total revenues	67,460		23,148		90,608
Cost of sales	30,827		15,769		46,596
Gross profit	36,633		7,379		44,012
Advertising and promotion	11,842		1,207		13,049
Contribution margin	$	24,791	$	6,172	30,963
Other operating expenses					17,939
Operating income					13,024
Other expense					7,674
Provision for income taxes					3,204
Income from continuing operations					2,146
Income from discontinued operations, net of income tax					32
Loss on sale of discontinued operations, net of income tax					—
Net income					$	2,178

-22-



	Nine Months Ended December 31, 2011
(In thousands)	OTC Healthcare		Household Cleaning		Consolidated
Net sales	$	234,712	$	69,966	$	304,678
Other revenues	552		1,859		2,411
Total revenues	235,264		71,825		307,089
Cost of sales	97,198		50,995		148,193
Gross profit	138,066		20,830		158,896
Advertising and promotion	34,746		3,834		38,580
Contribution margin	$	103,320	$	16,996	120,316
Other operating expenses					40,049
Operating income					80,267
Other expense					19,910
Provision for income taxes					23,130
Income from continuing operations					37,227
Income from discontinued operations, net of income tax					—
Loss on sale of discontinued operations, net of income tax					—
Net income					$	37,227



	Nine Months Ended December 31, 2010
(In thousands)	OTC Healthcare		Household Cleaning		Consolidated
Net sales	$	162,652	$	75,434	$	238,086
Other revenues	368		1,693		2,061
Total revenues	163,020		77,127		240,147
Cost of sales	64,477		51,097		115,574
Gross profit	98,543		26,030		124,573
Advertising and promotion	23,918		4,857		28,775
Contribution margin	$	74,625	$	21,173	95,798
Other operating expenses					38,277
Operating income					57,521
Other expense					18,808
Provision for income taxes					15,948
Income from continuing operations					22,765
Income from discontinued operations, net of income tax					591
Loss on sale of discontinued operations, net of income tax					(550		)
Net income					$	22,806

During the three and nine months ended December 31, 2011, approximately 96.2% and 96.3%, respectively, of our sales were made to customers in the United States and Canada, while during the three and nine months ended December 31, 2010, approximately 95.5% and 95.7%, respectively, of our sales were made to customers in the United States and Canada. Other than the United States, no individual geographical area accounted for more than 10% of net sales in any of the periods presented.

At December 31, 2011, substantially all of our long-term assets were located in the United States and have been allocated to the operating segments as follows:



(In thousands)	OTC Healthcare		Household Cleaning		Consolidated
Goodwill	$	146,307	$	7,389	$	153,696

Intangible assets
Indefinite-lived	568,664		119,820		688,484
Finite-lived	60,666		30,092		90,758
	629,330		149,912		779,242

	$	775,637	$	157,301	$	932,938

-23-


20.	Gain on Settlement

On June 15, 2011, we received a settlement payment of $8.0 million in the resolution of a pending litigation matter. We incurred costs of $2.9 million in pursuing this matter. Therefore, we recorded a pre-tax gain on settlement of $5.1 million net of costs incurred and $3.2 million after income tax effects for the nine months ended December 31, 2011. The $5.1 million pre-tax gain is included in other (income) expense, as this gain did not relate to our ongoing operations.

-24-

21. Condensed Consolidating Financial Statements

As described in Note 10, we, together with certain of our wholly-owned subsidiaries, have fully and unconditionally guaranteed, on a joint and several basis, the obligations of Prestige Brands, Inc. (a wholly-owned subsidiary of the Company) set forth in the Senior Notes Indenture, including, without limitation, the obligation to pay principal and interest with respect to the 2010 Senior Notes. The wholly-owned subsidiaries of the Company that have guaranteed the 2010 Senior Notes are as follows: Prestige Personal Care Holdings, Inc., Prestige Personal Care, Inc., Prestige Services Corp., Prestige Brands Holdings, Inc. (a Virginia corporation), Prestige Brands International, Inc., Medtech Holdings, Inc., Medtech Products Inc., The Cutex Company, The Denorex Company, The Spic and Span Company, and Blacksmith Brands, Inc. (collectively, the "Subsidiary Guarantors"). A significant portion of our operating income and cash flow is generated by our subsidiaries. As a result, funds necessary to meet Prestige Brands, Inc.'s debt service obligations are provided in part by distributions or advances from our subsidiaries. Under certain circumstances, contractual and legal restrictions, as well as the financial condition and operating requirements of our subsidiaries, could limit Prestige Brands, Inc.'s ability to obtain cash from our subsidiaries for the purpose of meeting our debt service obligations, including the payment of principal and interest on the 2010 Senior Notes. Although holders of the 2010 Senior Notes will be direct creditors of the guarantors of the 2010 Senior Notes by virtue of the guarantees, we have indirect subsidiaries located primarily in the United Kingdom and in the Netherlands (collectively, the "Non-Guarantor Subsidiaries") that have not guaranteed the 2010 Senior Notes, and such subsidiaries will not be obligated with respect to the 2010 Senior Notes. As a result, the claims of creditors of the Non-Guarantor Subsidiaries will effectively have priority with respect to the assets and earnings of such companies over the claims of the holders of the 2010 Senior Notes.

Presented below are supplemental Condensed Consolidating Balance Sheets as of December 31, 2011 and March 31, 2011, Condensed Consolidating Statements of Operations for the three and nine months ended December 31, 2011 and 2010, and Condensed Consolidating Statements of Cash Flows for the nine months ended December 31, 2011 and 2010. Such consolidating information includes separate columns for:

a) Prestige Brands Holdings, Inc., the parent,

b) Prestige Brands, Inc., the issuer,

c) Combined Subsidiary Guarantors,

d) Combined Non-Guarantor Subsidiaries, and

e) Elimination entries necessary to consolidate the Company and all of its subsidiaries.

The Condensed Consolidating Financial Statements are presented using the equity method of accounting for investments in wholly-owned subsidiaries. Under the equity method, the investments in subsidiaries are recorded at cost and adjusted for our share of the subsidiaries' cumulative results of operations, capital contributions, distributions and other equity changes. The elimination entries principally eliminate investments in subsidiaries and intercompany balances and transactions. The financial information in this note should be read in conjunction with the Consolidated Financial Statements presented and other notes related thereto contained in this Quarterly Report on Form 10-Q for the quarter ended December 31, 2011.

-25-

Condensed Consolidating Statement of Operations

Three Months Ended December 31, 2011



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	83,572		$	21,088		$	1,139		$	—		$	105,799
Other revenues	—			196			255			284			(284		)	451
Total revenues	—			83,768			21,343			1,423			(284		)	106,250

Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			35,138			15,799			475			(284		)	51,128
Gross profit	—			48,630			5,544			948			—			55,122

Advertising and promotion	—			13,547			1,103			624			—			15,274
General and administrative	1,206			9,610			2,450			389			—			13,655
Depreciation and amortization	134			1,954			458			17			—			2,563
Total operating expenses	1,340			25,111			4,011			1,030			—			31,492

Operating income (loss)	(1,340		)	23,519			1,533			(82		)	—			23,630

Other (income) expense
Interest income	(11,790		)	(2,267		)	—			(60		)	14,116			(1		)
Interest expense	—			19,384			2,849			—			(14,116		)	8,117
Equity in income of subsidiaries	(3,125		)	—			—			—			3,125			—
Total other (income) expense	(14,915		)	17,117			2,849			(60		)	3,125			8,116

Income (loss) before income taxes	13,575			6,402			(1,316		)	(22		)	(3,125		)	15,514

Provision (benefit) for income taxes	4,065			2,430			(509		)	18			—			6,004
Net income (loss)	$	9,510		$	3,972		$	(807	)	$	(40	)	$	(3,125	)	$	9,510

-26-

Condensed Consolidating Statement of Operations

Three Months Ended December 31, 2010



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	66,089		$	22,790		$	1,198		$	—		$	90,077
Other revenues	—			173			358			336			(336		)	531
Total revenues	—			66,262			23,148			1,534			(336		)	90,608

Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			30,662			15,769			501			(336		)	46,596
Gross profit	—			35,600			7,379			1,033			—			44,012

Advertising and promotion	3			11,232			1,206			608			—			13,049
General and administrative	(74		)	12,445			2,797			258			—			15,426
Depreciation and amortization	111			1,921			463			18			—			2,513
Total operating expenses	40			25,598			4,466			884			—			30,988

Operating income (loss)	(40		)	10,002			2,913			149			—			13,024

Other (income) expense
Interest income	(13,073		)	(2,258		)	—			(85		)	15,416			—
Interest expense	—			19,534			3,556			—			(15,416		)	7,674
Equity in income of subsidiaries	4,698			—			—			—			(4,698		)	—
Total other (income) expense	(8,375		)	17,276			3,556			(85		)	(4,698		)	7,674

Income (loss) from continuing operations before income taxes	8,335			(7,274		)	(643		)	234			4,698			5,350

Provision (benefit) for income taxes	6,157			(2,797		)	(245		)	89			—			3,204
Income (loss) from continuing operations	2,178			(4,477		)	(398		)	145			4,698			2,146

Discontinued operations
Income from discontinued operations, net of income tax	—			17			15			—			—			32
Loss on sale of discontinued operations, net of income tax	—			—			—			—			—			—
Net income (loss)	$	2,178		$	(4,460	)	$	(383	)	$	145		$	4,698		$	2,178

-27-

Condensed Consolidating Statement of Operations

Nine Months Ended December 31, 2011



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	231,662		$	69,964		$	3,052		$	—		$	304,678
Other revenues	—			552			1,859			1,284			(1,284		)	2,411
Total revenues	—			232,214			71,823			4,336			(1,284		)	307,089

Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			97,227			50,995			1,255			(1,284		)	148,193
Gross profit	—			134,987			20,828			3,081			—			158,896

Advertising and promotion	—			33,643			3,834			1,103			—			38,580
General and administrative	627			22,882			7,891			966			—			32,366
Depreciation and amortization	412			5,843			1,375			53			—			7,683
Total operating expenses	1,039			62,368			13,100			2,122			—			78,629

Operating income (loss)	(1,039		)	72,619			7,728			959			—			80,267

Other (income) expense
Interest income	(36,663		)	(6,795		)	—			(173		)	43,627			(4		)
Interest expense	—			58,713			9,891			—			(43,627		)	24,977
Gain on settlement	(5,063		)	—			—			—			—			(5,063		)
Equity in income of subsidiaries	(12,119		)	—			—			—			12,119			—
Total other (income) expense	(53,845		)	51,918			9,891			(173		)	12,119			19,910

Income (loss) before income taxes	52,806			20,701			(2,163		)	1,132			(12,119		)	60,357

Provision (benefit) for income taxes	15,579			8,000			(837		)	388			—			23,130
Net income (loss)	$	37,227		$	12,701		$	(1,326	)	$	744		$	(12,119	)	$	37,227

-28-

Condensed Consolidating Statement of Operations

Nine Months Ended December 31, 2010



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors		Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	159,772		$	75,434	$	2,880		$	—		$	238,086
Other revenues	—			369			1,692		1,327			(1,327		)	2,061
Total revenues	—			160,141			77,126		4,207			(1,327		)	240,147

Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			64,680			51,097		1,124			(1,327		)	115,574
Gross profit	—			95,461			26,029		3,083			—			124,573

Advertising and promotion	2			22,864			4,858		1,051			—			28,775
General and administrative	(225		)	22,651			8,196		319			—			30,941
Depreciation and amortization	338			5,559			1,388		51			—			7,336
Total operating expenses	115			51,074			14,442		1,421			—			67,052

Operating income (loss)	(115		)	44,387			11,587		1,662			—			57,521

Other (income) expense
Interest income	(39,142		)	(6,884		)	—		(132		)	46,158			—
Interest expense	—			54,021			10,645		—			(46,158		)	18,508
Loss on extinguishment of debt	—			300			—		—			—			300
Equity in income of subsidiaries	110			—			—		—			(110		)	—
Total other (income) expense	(39,032		)	47,437			10,645		(132		)	(110		)	18,808

Income (loss) from continuing operations before income taxes	38,917			(3,050		)	942		1,794			110			38,713

Provision (benefit) for income taxes	16,111			(993		)	361		469			—			15,948
Income (loss) from continuing operations	22,806			(2,057		)	581		1,325			110			22,765

Discontinued operations
Income from discontinued operations, net of income tax	—			578			13		—			—			591
Loss on sale of discontinued operations, net of income tax	—			(550		)	—		—			—			(550		)
Net income (loss)	$	22,806		$	(2,029	)	$	594	$	1,325		$	110		$	22,806

-29-

Condensed Consolidating Balance Sheet

December 31, 2011



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Assets
Current assets
Cash and cash equivalents	$	3,545		$	—		$	—		$	894		$	—		$	4,439
Accounts receivable, net	37			41,166			8,111			849			—			50,163
Inventories	—			33,975			8,973			631			—			43,579
Deferred income tax assets	220			4,731			589			—			—			5,540
Prepaid expenses and other current assets	1,285			872			5			—			—			2,162
Total current assets	5,087			80,744			17,678			2,374			—			105,883

Property and equipment, net	860			268			106			4			—			1,238
Goodwill	—			146,306			7,390			—			—			153,696
Intangible assets, net	—			628,938			149,912			392			—			779,242
Other long-term assets	(1		)	5,789			—			—			—			5,788
Intercompany receivable	1,020,576			937,176			105,748			6,972			(2,070,472		)	—
Investment in subsidiary	456,119			—			—			—			(456,119		)	—
Total Assets	$	1,482,641		$	1,799,221		$	280,834		$	9,742		$	(2,526,591	)	$	1,045,847

Liabilities and Stockholders' Equity
Current liabilities
Accounts payable	$	1,890		$	13,914		$	7,437		$	736		$	—		$	23,977
Accrued interest payable	—			5,181			—			—			—			5,181
Other accrued liabilities	4,446			29,101			1,568			824			(12,034		)	23,905
Total current liabilities	6,336			48,196			9,005			1,560			(12,034		)	53,063

Long-term debt
Principal amount	—			434,000			—			—			—			434,000
Less unamortized discount	—			(4,368		)	—			—			—			(4,368		)
Long-term debt, net of unamortized discount	—			429,632			—			—			—			429,632

Deferred income tax liabilities	(4,235		)	138,842			26,812			83			—			161,502

Intercompany payable	916,629			968,697			172,479			632			(2,058,437		)	—
Intercompany equity in subsidiaries	162,261			—			—			—			(162,261		)	—

Total Liabilities	1,080,991			1,585,367			208,296			2,275			(2,232,732		)	644,197

Stockholders' Equity
Common stock	504			—			—			—			—			504
Additional paid-in capital	390,863			337,458			118,638			24			(456,120		)	390,863
Treasury stock, at cost - 181 shares	(687		)	—			—			—			—			(687		)
Accumulated other comprehensive loss, net of tax	(70		)	—			—			(70		)	70			(70		)
Retained earnings (accumulated deficit)	11,040			(129,331		)	(46,100		)	13,240			162,191			11,040
Intercompany dividends	—			5,727			—			(5,727		)	—			—
Total Stockholders' Equity	401,650			213,854			72,538			7,467			(293,859		)	401,650

Total Liabilities and Stockholders' Equity	$	1,482,641		$	1,799,221		$	280,834		$	9,742		$	(2,526,591	)	$	1,045,847

-30-

Condensed Consolidating Balance Sheet

March 31, 2011



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Assets
Current assets
Cash and cash equivalents	$	12,698		$	—		$	—		$	636		$	—		$	13,334
Accounts receivable, net	13			34,835			8,842			703			—			44,393
Inventories	—			31,023			8,050			678			—			39,751
Deferred income tax assets	646			4,168			477			1			—			5,292
Prepaid expenses and other current assets	4,505			156			150			1			—			4,812
Total current assets	17,862			70,182			17,519			2,019			—			107,582

Property and equipment, net	1,131			127			173			13			—			1,444
Goodwill	—			147,506			7,390			—			—			154,896
Intangible assets, net	—			634,704			151,220			437			—			786,361
Other long-term assets	—			6,635			—			—			—			6,635
Intercompany receivable	1,007,260			954,317			92,251			4,558			(2,058,386		)	—
Investment in subsidiary	456,119			—			—			—			(456,119		)	—
Total Assets	$	1,482,372		$	1,813,471		$	268,553		$	7,027		$	(2,514,505	)	$	1,056,918

Liabilities and Stockholders' Equity
Current liabilities
Accounts payable	$	1,920		$	14,656		$	4,627		$	412		$	—		$	21,615
Accrued interest payable	—			10,313			—			—			—			10,313
Other accrued liabilities	15,555			15,134			(7,382		)	(1,027		)	—			22,280
Total current liabilities	17,475			40,103			(2,755		)	(615		)	—			54,208

Long-term debt
Principal amount	—			492,000			—			—			—			492,000
Less unamortized discount	—			(5,055		)	—			—			—			(5,055		)
Long-term debt, net of unamortized discount	—			486,945			—			—			—			486,945

Deferred income tax liabilities	(2,846		)	132,549			24,135			95			—			153,933

Intercompany payable	931,601			952,721			173,310			754			(2,058,386		)	—
Intercompany equity in subsidiaries	174,310			—			—			—			(174,310		)	—

Total Liabilities	1,120,540			1,612,318			194,690			234			(2,232,696		)	695,086

Stockholders' Equity
Common stock	503			—			—			—			—			503
Additional paid-in capital	387,932			337,458			118,637			24			(456,119		)	387,932
Treasury stock, at cost - 160 shares	(416		)	—			—			—			—			(416		)
(Accumulated deficit) retained earnings	(26,187		)	(142,032		)	(44,774		)	12,496			174,310			(26,187		)
Intercompany dividends	—			5,727			—			(5,727		)	—			—
Total Stockholders' Equity	361,832			201,153			73,863			6,793			(281,809		)	361,832

Total Liabilities and Stockholders' Equity	$	1,482,372		$	1,813,471		$	268,553		$	7,027		$	(2,514,505	)	$	1,056,918

-31-

Condensed Consolidating Statement of Cash Flows

Nine Months Ended December 31, 2011



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer				Combined Subsidiary Guarantors				Combined Non- Guarantor Subsidiaries				Eliminations				Consolidated
Operating Activities
Net income (loss)	$	37,227		$	12,701			$	(1,326	)		$	744			$	(12,119	)		$	37,227
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	412			5,843				1,375				53				—				7,683
Deferred income taxes	(963		)	5,718				2,565				1				—				7,321
Amortization of deferred financing costs	—			847				—				—				—				847
Stock-based compensation costs	2,360			—				—				—				—				2,360
Amortization of debt discount	—			687				—				—				—				687
Changes in operating assets and liabilities
Accounts receivable	(23		)	(6,331		)		731				(193		)		—				(5,816		)
Inventories	—			(2,951		)		(924		)		25				—				(3,850		)
Prepaid expenses and other current assets	3,218			(715		)		145				2				—				2,650
Accounts payable	(29		)	(748		)		2,810				359				—				2,392
Accrued liabilities	(14,662		)	14,860				(3,084		)		(622		)		—				(3,508		)
Intercompany activity, net	26,866			(34,020		)		(2,292		)		(200		)		9,646				—
Net cash provided by (used in) operating activities	54,406			(4,109		)		—				169				(2,473		)		47,993

Investing Activities
Purchases of equipment	(140		)	(218		)		—				—				—				(358		)
Proceeds from escrow of Blacksmith acquisition	—			1,200				—				—				—				1,200
Intercompany activity, net	1,200			(1,200		)		—				—				—				—
Net cash provided by (used in) investing activities	1,060			(218		)	—	—			—	—			—	—			—	842

Financing Activities
Repayment of long-term debt	—			(58,000		)		—				—				—				(58,000		)
Proceeds from exercise of stock options	572			—				—				—				—				572
Shares surrendered as payment of tax withholding	(271		)	—				—				—				—				(271		)
Intercompany activity, net	(64,920		)	62,327				—				120				2,473				—
Net cash (used in) provided by financing activities	(64,619		)	4,327				—				120				2,473				(57,699		)

Effect of exchange rate changes on cash and cash equivalents	—			—				—				(31		)		—				(31		)
(Decrease) increase in cash	(9,153		)	—				—				258				—				(8,895		)
Cash - beginning of period	12,698			—				—				636				—				13,334

Cash - end of period	$	3,545		$	—			$	—			$	894			$	—			$	4,439

-32-

Condensed Consolidating Statement of Cash Flows

Nine Months Ended December 31, 2010



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non-Guarantor Subsidiaries			Eliminations			Consolidated
Operating Activities
Net income (loss)	$	22,806		$	(2,029	)	$	594		$	1,325		$	110		$	22,806
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	338			5,789			1,388			50			—			7,565
Loss on sale of discontinued operations	—			890			—			—			—			890
Deferred income taxes	(1,039		)	3,768			2,862			—			—			5,591
Amortization of deferred financing costs	—			767			—			—			—			767
Stock-based compensation costs	2,751			—			—			—			—			2,751
Loss on extinguishment of debt	—			300			—			—			—			300
Amortization of debt discount	—			480			—			—			—			480
Loss on disposal of equipment	3			105			20			3			—			131
Changes in operating assets and liabilities, net of effects of purchases of businesses:
Accounts receivable	1,037			3,624			2,985			(316		)	—			7,330
Inventories	—			4,696			(1,712		)	(170		)	—			2,814
Inventories held for sale	—			1,114			—			—			—			1,114
Prepaid expenses and other current assets	3,404			(395		)	157			—			—			3,166
Accounts payable	(1,631		)	(746		)	852			471			—			(1,054		)
Accrued liabilities	(2,069		)	11,567			(2,778		)	288			—			7,008
Intercompany activity, net	—			—			—			—			—			—
Net cash provided by operating activities	25,600			29,930			4,368			1,651			110			61,659

Investing Activities
Purchases of equipment	(358		)	(44		)	—			(3		)	—			(405		)
Proceeds from sale of discontinued operations	—			4,122			—			—			—			4,122
Acquisition of Blacksmith, net of cash acquired	(221		)	(201,823		)	—			—			—			(202,044		)
Net cash used in investing activities	(579		)	(197,745		)	—			(3		)	—			(198,327		)

Financing Activities
Proceeds from issuance of Senior Notes	—			100,250			—			—			—			100,250
Proceeds from issuance of Senior Term Loan	—			112,936			—			—			—			112,936
Payment of deferred financing costs	—			(648		)	—			—			—			(648		)
Repayment of long-term debt	—			(33,587		)	—			—			—			(33,587		)
Proceeds from exercise of stock options	150			—			—			—			—			150
Shares surrendered as payment of tax withholding	(264		)	—			—			—			—			(264		)
Intercompany activity, net	17,101			(11,136		)	(4,368		)	(1,487		)	(110		)	—
Net cash provided by (used in) financing activities	16,987			167,815			(4,368		)	(1,487		)	(110		)	178,837

Increase in cash	42,008			—			—			161			—			42,169
Cash - beginning of period	40,644			—			—			453			—			41,097

Cash - end of period	$	82,652		$	—		$	—		$	614		$	—		$	83,266

-33-

22. Subsequent Events

Acquisition and refinancing:

On January 24, 2012, we priced, and on January 31, 2012, we completed, an offering of $250.0 million in aggregate principal amount of 8.125% senior notes due 2020 (the “Notes”). In addition, on January 31, 2012, we completed, subject to a post-closing inventory adjustment, the acquisition of 15 North American over-the-counter healthcare brands owned by GSK and its affiliates (the “GSK Brands I”) for $615.0 million in cash, including the related contracts, trademarks and inventory. We also entered into new senior secured term loan and revolving credit facilities and ratably secured our existing 8.25% Senior Notes due 2018 with the new term loan facility.

The Notes will be senior unsecured obligations and will be guaranteed by us and certain of our domestic subsidiaries. We are using the net proceeds from the Notes offering, together with borrowings under the new senior secured term loan facility, to finance the acquisition of 17 North American over-the-counter from GSK and its affiliates, to repay our existing senior secured credit facilities, to pay fees and expenses incurred in connection with these transactions and for general corporate purposes.

On January 31, 2012, in connection with the completed acquisition of the GSK Brands I, we entered into a New Senior Secured Credit Facility which consists of (i) a $660.0 million term loan facility (“New Term Loan Facility”) with a seven-year maturity and (ii) a $50.0 million asset-based revolving credit facility (“New ABL Revolving Credit Facility”) with a five-year maturity. Borrowings under our New Senior Secured Credit Facility bear interest at a rate per annum (i) with respect to term loans, at our option, at the Eurocurrency Rate (as defined in the agreement) plus 4.00% or the Base Rate (as defined in the agreement) plus 3.00%, (ii) with respect to revolving loans, at our option, at the Eurocurrency Rate plus a range of 1.75% to 2.25% depending on Excess Availability (as defined in the agreement) or the Base Rate plus a range of 0.75% to 1.25% depending on Excess Availability, and (iii) with respect to swing line loans, the Base Rate plus a range of 0.75% to 1.25% depending on Excess Availability. We will be required to make quarterly payments each equal to 0.25% of the original principal amount of the term loan made on the closing date, with the balance expected to be due on the seventh anniversary of the closing date.

The GSK Brands I include BC, Goody's and Ecotrin brands of pain relievers; Beano, Gaviscon, Phazyme, Tagamet and Fiber Choice gastrointestinal (“GI”) brands; and the Sominex sleep aid brand. These brands are complementary to our existing OTC Healthcare portfolio.

We acquired the GSK Brands I pursuant to the terms of that certain purchase agreement we entered into on December 20, 2011 with GSK and its affiliates. We also entered into a separate purchase agreement on December 20, 2011 with GSK and its affiliates to acquire Debrox and Gly-Oxide brands (the "GSK Brands II") in the United States for $45.0 million in cash, including the related contracts, trademarks and inventory, subject to a post-closing inventory adjustment. The GSK Brands II are also complementary to our existing OTC Healthcare portfolio. The acquisition of the GSK Brands II is expected to be completed no later than June 30, 2012.

These acquisitions will be accounted for in accordance with the Business Combinations Topic of the ASC, which requires that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition. As of the date of this Quarterly Report on Form 10−Q, we have not yet completed the initial accounting for the acquisition, and the acquisition−date fair values of the acquired assets and assumed liabilities have not yet been determined.

Equity Awards:

On January 25, 2012, the Compensation Committee of our Board of Directors granted 95,000 shares of restricted stock units to certain members of executive management. The restricted stock units will vest in equal annual installments over a three year period on the anniversary date of the grants.

-34-


ITEM 2.	MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion of our financial condition and results of operations should be read together with the Consolidated Financial Statements and the related notes included in this Quarterly Report on Form 10-Q, as well as our Annual Report on Form 10-K for the fiscal year ended March 31, 2011. This discussion and analysis may contain forward-looking statements that involve certain risks, assumptions and uncertainties. Future results could differ materially from the discussion that follows for many reasons, including the factors described in Part I, Item 1A., “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended March 31, 2011, as well as those described in future reports filed with the SEC.

See also “Cautionary Statement Regarding Forward-Looking Statements” on page 51 of this Quarterly Report on Form 10-Q.

General

We are engaged in the marketing, sales and distribution of brand name Over-the-Counter ("OTC") Healthcare and Household Cleaning products to mass merchandisers, drug stores, supermarkets and dollar and club stores primarily in the United States, Canada and certain other international markets. We continue to use the strength of our brands, our established retail distribution network, a low-cost operating model and our experienced management team as a competitive advantage to grow our presence in these categories and, as a result, grow our sales and profits.

We have grown our product portfolio both organically and through acquisitions. We develop our existing brands by investing in new product lines, brand extensions and strong advertising support. Acquisitions of OTC brands have also been an important part of our growth strategy. We have acquired strong and well-recognized brands from consumer products and pharmaceutical companies. While many of these brands have long histories of brand development and investment, we believe that, at the time we acquired them, most were considered “non-core” by their previous owners. As a result, these acquired brands did not benefit from adequate management focus and marketing support during the period prior to their acquisition, which created significant opportunities for us to reinvigorate these brands and improve their performance post-acquisition. After adding a brand to our portfolio, we seek to increase its sales, market share and distribution in both existing and new channels through our established retail distribution network. This is achieved through increased spending on advertising and promotional support, new sales and marketing strategies, improved packaging and formulations, and innovative development of brand extensions.

Acquisitions and Divestitures

Acquisition of GlaxoSmithKline OTC Brands

On December 20, 2011, we entered into two separate agreements with GlaxoSmithKline plc ("GSK") to acquire a total of 17 North American OTC pharmaceutical brands for $660.0 million in cash. On January 31, 2012, we completed the acquisition of 15 of these brands for $615.0 million. The acquisition of the remaining two brands is expected to be completed no later than June 30, 2012. The acquisition and the agreements are more fully described in Note 22- Subsequent Events to the Consolidated Financial Statements in this Quarterly Report on Form 10-Q. The acquisition did not impact any period covered in this Quarterly Report on Form 10-Q, except that certain costs of approximately $4.9 million related to the acquisition were expensed as incurred during the three and nine months ended December 31, 2011.

Blacksmith Acquisition

In connection with this acquisition, we acquired five leading consumer OTC brands: Efferdent, Effergrip, PediaCare, Luden's, and NasalCrom. The acquisition of the five brands enhances our position in the OTC market. Additionally, we believe that these brands will benefit from a targeted advertising and marketing program, as well as our business model of outsourcing manufacturing and the elimination of redundant operations. The purchase price was funded by cash provided by the issuance of long-term debt and additional bank borrowings, which are discussed further in Note 10 to the Consolidated Financial Statements in this Quarterly Report on Form 10-Q.

The acquisition was accounted for in accordance with the Business Combinations topic of the Accounting Standards Codification

-35-

(“ASC"), which requires that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition.

The following table summarizes our allocation of the $203.4 million purchase price to the assets we acquired and liabilities we assumed in the Blacksmith acquisition:



(In thousands)	November 1, 2010

Cash acquired	$	2,507
Accounts receivable, net	17,473
Other receivables	1,198
Income taxes receivable	5
Inventories	22,155
Prepaids and other current assets	44
Property, plant and equipment, net	226
Goodwill	42,207
Trademarks	165,346
Other long-term assets	19
Total assets acquired	251,180

Accounts payable	7,060
Accrued expenses	5,212
Income taxes payable	2,031
Deferred income taxes	33,526
Total liabilities assumed	47,829

Total purchase price	$	203,351

The fair value of the trademarks is comprised of $158.0 million of non-amortizable intangible assets and $7.3 million of amortizable intangible assets. We are amortizing the purchased amortizable intangible assets on a straight-line basis over an estimated weighted average useful life of 15 years. The weighted average remaining life for amortizable intangible assets at December 31, 2011 was 13.8 years.

Dramamine Acquisition

On January 6, 2011, we acquired certain assets comprising the Dramamine brand in the United States. The purchase price was

$77.1 million in cash, after a $0.1 million post-closing inventory adjustment and including transaction costs of $1.2 million incurred in the acquisition. The purchase price was funded by cash on hand.

The acquisition was accounted for in accordance with the Business Combinations topic of the ASC. Accordingly, as the Dramamine assets acquired do not constitute a business, as defined in the ASC, we have accounted for the transaction as an asset acquisition. The total consideration paid, including transaction costs, have been allocated to the tangible and intangible assets acquired based upon their relative fair values at the date of acquisition.

-36-



(In thousands)	January 6, 2011

Inventories	$	1,249
Trademark	75,866
Total purchase price	$	77,115

The $75.9 million fair value of the acquired Dramamine trademark was comprised solely of non-amortizable intangible assets.

Discontinued Operations and Sale of Certain Assets

On September 1, 2010, we sold certain assets related to the Cutex nail polish remover brand for $4.1 million. In accordance with the Discontinued Operations topic of the ASC, we reclassified the related operating results as discontinued operations in the Consolidated Financial Statements and related notes in this Quarterly Report on Form 10-Q for all periods presented. We recognized a loss of $0.9 million on a pre-tax basis and $0.6 million, net of tax effects of $0.3 million, on the sale in the second quarter of 2011. As a result of the divestiture of Cutex, which comprised a substantial majority of the assets in our previously reported Personal Care segment, we reclassified the then remaining assets of the Personal Care segment to the OTC Healthcare segment for all periods presented.

The following table summarizes the results of discontinued operations:



(In thousands)	Three Months Ended December 31,				Nine Months Ended December 31,
	2011		2010		2011		2010
Components of Income
Revenues	$	—	$	84	$	—	$	4,027
Income from discontinued operations, net of income tax	—		32		—		591

Three Months Ended December 31, 2011 compared to the Three Months Ended December 31, 2010

Revenues



	Three Months Ended December 31,
	2011			2010			Increase
(In thousands, except percentages)	Revenues		%	Revenues		%	(Decrease)			%
Revenues
OTC Healthcare	$	84,906	79.9	$	67,460	74.5	$	17,446		25.9
Household Cleaning	21,344		20.1	23,148		25.5	(1,804		)	(7.8	)

	$	106,250	100.0	$	90,608	100.0	$	15,642		17.3

Revenues for the three months ended December 31, 2011 were $106.3 million, an increase of $15.6 million, or 17.3%, versus the three months ended December 31, 2010. Revenues for the OTC Healthcare segment increased $17.4 million or 25.9%, primarily due to the higher revenues of $16.6 million from sales of the acquired Blacksmith and Dramamine products, while revenues for the Household Cleaning segment decreased by 7.8% versus the comparable period in the prior year. Revenues from customers outside of North America, which represent 3.8% of total revenues, decreased by $0.1 million, or 2.5%, during the three months ended December 31, 2011 compared to the three months ended December 31, 2010.

OTC Healthcare Segment

Revenues for the OTC Healthcare segment increased $17.4 million, or 25.9%, during the three months ended December 31, 2011 versus the three months ended December 31, 2010. The increase in revenues was primarily due to revenues of $16.6 million from sales of the acquired Blacksmith and Dramamine products and higher revenues for Little Remedies, The Doctor's and Clear Eyes, which were partially offset by revenue decreases for Compound W and Chloraseptic. The Little Remedies revenue increase was a result of new product introductions and distribution gains for existing products. The Doctor's revenue benefited from the recovery of distribution at our largest customer. The Clear Eyes revenue increase was a result of growth in our Allergy / Redness business. Compound W revenues declined due to competitive pressure. Chloraseptic revenues declined versus the same period in the prior year mainly due to a soft cough and cold season and fewer sore throat incidences.

-37-

Household Cleaning Segment

Revenues for the Household Cleaning segment decreased by $1.8 million, or 7.8%, during the three months ended December 31, 2011 versus the three months ended December 31, 2010. Weaker Comet sales were partially offset by stronger performance of Spic and Span. Comet revenues decreased primarily due to decreased consumer demand of Comet Bath Sprays and lower promotional activity. Spic and Span revenues continued to benefit from increased promotional activity, expanded distribution and consumer demand for Spic and Span sprays and Chore Boy copper scrubbers in the three months ended December 31, 2011 versus the three months ended December 31, 2010.

Gross Profit



	Three Months Ended December 31,
	2011			2010			Increase
(In thousands, except percentages)	Gross Profit		%	Gross Profit		%	(Decrease)			%
Gross Profit
OTC Healthcare	$	49,577	58.4	$	36,633	54.3	$	12,944		35.3
Household Cleaning	5,545		26.0	7,379		31.9	(1,834		)	(24.9	)

	$	55,122	51.9	$	44,012	48.6	$	11,110		25.2

Gross profit for the three months ended December 31, 2011 increased $11.1 million, or 25.2%, when compared with the three months ended December 31, 2010. As a percent of total revenues, gross profit increased from 48.6% in the three months ended December 31, 2010 to 51.9% in the three months ended December 31, 2011. The higher gross profit was primarily the result of the brands acquired from Blacksmith and the Dramamine brand, which increased gross profit by $8.6 million, as the prior year period included a $3.5 million inventory step-up charge related to the Blacksmith acquisition, and gross profit increases in our legacy OTC Healthcare brands of $4.3 million, including gross profit increases in our legacy core OTC Healthcare brands of $0.8 million. These gains were partially offset by decreases in gross profit from our Household Cleaning segment, primarily Comet.

The increase in gross profit as a percent of revenues is primarily due to the inventory step-up charge in the prior year period resulting in an increase of 3.9%, which was slightly offset by the realization of lower margins from the acquired Blacksmith products and increased expenses from promotional activity in the Household Cleaning segment.

OTC Healthcare Segment

Gross profit for the OTC Healthcare segment increased $12.9 million, or 35.3%, during the three months ended December 31, 2011 versus the three months ended December 31, 2010. As a percent of OTC Healthcare revenues, gross profit increased from 54.3% during the three months ended December 31, 2010 to 58.4% during the three months ended December 31, 2011. The higher gross profit was primarily the result of the brands acquired from Blacksmith and the Dramamine brand, which increased gross profit by $8.6 million, as the prior year period included a $3.5 million inventory step-up charge related to the Blacksmith acquisition, and gross profit increases in our legacy OTC Healthcare brands of $4.3 million, including gross profit increases in our legacy core OTC Healthcare brands of $0.8 million. The increase in gross profit as a percent of revenues is primarily due to the inventory step-up charge in the prior year period resulting in an increase of 5.3%, which was slightly offset by the realization of lower margins from the acquired Blacksmith products and the lower gross profit margins from the legacy core OTC Healthcare products.

Household Cleaning Segment

Gross profit for the Household Cleaning segment decreased by $1.8 million, or 24.9%, during the three months ended December 31, 2011 versus the three months ended December 31, 2010. As a percent of Household Cleaning revenue, gross profit decreased from 31.9% during the three months ended December 31, 2010 to 26.0% during the three months ended December 31, 2011. The decrease in gross profit percentage was primarily the result of the lower revenues and resulting gross margins from Comet.

-38-

Contribution Margin



	Three Months Ended December 31,
	2011			2010
(In thousands, except percentages)	Contribution Margin		%	Contribution Margin		%	Increase (Decrease)			%
Contribution Margin
OTC Healthcare	$	35,407	41.7	$	24,791	36.7	$	10,616		42.8
Household Cleaning	4,441		20.8	6,172		26.7	(1,731		)	(28.0	)

	$	39,848	37.5	$	30,963	34.2	$	8,885		28.7

Contribution margin, a non-GAAP financial measure which is defined as gross profit less advertising and promotional expenses, increased $8.9 million, or 28.7%, during the three months ended December 31, 2011 versus the three months ended December 31, 2010. The contribution margin increase was primarily the result of the higher gross profit as previously discussed, offset by higher advertising and promotional costs in the OTC Healthcare segment. The acquired Blacksmith and Dramamine brands added $6.8 million, while the legacy business added $2.1 million to the contribution margin.

OTC Healthcare Segment

Contribution margin for the OTC Healthcare segment increased $10.6 million, or 42.8%, during the three months ended December 31, 2011 versus the three months ended December 31, 2010. The contribution margin increase was primarily the result of the $6.8 million contribution margin increase related to the acquired Blacksmith and Dramamine products, while the legacy OTC Healthcare business added $3.8 million. Advertising and promotional spending increased $2.3 million, or 19.7%, primarily to support the acquired Blacksmith products and, to a lesser extent, the legacy OTC Healthcare brands.

Household Cleaning Segment

Contribution margin for the Household Cleaning segment decreased $1.7 million, or 28.0%, during the three months ended December 31, 2011 versus the three months ended December 31, 2010. The contribution margin decrease was the result of the decrease in gross profit as previously discussed, partially offset by a $0.1 million, or 8.5%, decrease in advertising and promotional spending. The decrease in advertising and promotional spending primarily related to a shift in the timing of Household Cleaning promotional activities that occurred in 2010.

General and Administrative

General and administrative expenses were $13.7 million for the three months ended December 31, 2011 versus $15.4 million for the three months ended December 31, 2010. The decrease in general and administrative expenses was primarily due to the incurrence of $6.9 million of transaction and severance costs associated with the Blacksmith acquisition in the prior year period, offset by $4.9 million of transaction related costs in the current year period.

Depreciation and Amortization

Depreciation and amortization expense was $2.6 million for the three months ended December 31, 2011 and $2.5 million for the three months ended December 31, 2010.

Interest Expense

Net interest expense was $8.1 million during the three months ended December 31, 2011 versus $7.7 million during the three months ended December 31, 2010. The increase in interest expense was primarily the result of a higher level of indebtedness outstanding related to the Blacksmith and Dramamine acquisitions. The cost of borrowing decreased to 7.3% for the three months ended December 31, 2011 from 7.6% for the three months ended December 31, 2010, while the average indebtedness outstanding increased from $402.5 million during the three months ended December 31, 2010 to $443.0 million during the three months ended December 31, 2011, due to increased debt issued for the Blacksmith and Dramamine acquisitions.

Income Taxes

The provision for income taxes during the three months ended December 31, 2011 was $6.0 million versus $3.2 million during the three months ended December 31, 2010. The effective tax rate during the three months ended December 31, 2011 was 38.7% versus 59.9% during the three months ended December 31, 2010. The decrease in the effective tax rate is primarily due to $0.8 million of non-deductible transaction expenses related to the Blacksmith acquisition and a $0.3 million charge for our deferred state tax rate incurred in the prior year period. The estimated effective tax rate for the remaining quarter of the fiscal year ending March 31, 2012 is expected to be 38.7%, excluding the impact of discrete items that may occur.

-39-

Nine Months Ended December 31, 2011 compared to the Nine Months Ended December 31, 2010

Revenues



	Nine Months Ended December 31,
	2011			2010			Increase
(In thousands, except percentages)	Revenues		%	Revenues		%	(Decrease)			%
Revenues
OTC Healthcare	$	235,264	76.6	$	163,020	67.9	$	72,244		44.3
Household Cleaning	71,825		23.4	77,127		32.1	(5,302		)	(6.9	)

	$	307,089	100.0	$	240,147	100.0	$	66,942		27.9

Revenues for the nine months ended December 31, 2011 were $307.1 million, an increase of $66.9 million, or 27.9%, versus the nine months ended December 31, 2010. Revenues for the OTC Healthcare segment increased $72.2 million or 44.3%, primarily due to revenues of $68.7 million from sales of the acquired Blacksmith and Dramamine products, while revenues for the Household Cleaning segment decreased by 6.9% versus the comparable period in the prior year. Revenues from customers outside of North America, which represent 3.7% of total revenues, increased by $0.9 million, or 8.3%, during the nine months ended December 31, 2011 compared to the nine months ended December 31, 2010.

OTC Healthcare Segment

Revenues for the OTC Healthcare segment increased $72.2 million, or 44.3%, during the nine months ended December 31, 2011 versus the nine months ended December 31, 2010. The increase in revenues was primarily due to revenues of $68.7 million from sales of the acquired Blacksmith and Dramamine products. Additionally, we increased advertising and promotional activities for our legacy OTC Healthcare brands, which resulted in increased shipments to retailers. Revenue increases for Little Remedies, Clear Eyes and The Doctor's were partially offset by revenue decreases in our other OTC Healthcare brands. Our core OTC Healthcare brands have continued to benefit from increased advertising and promotion investment, which has translated into organic sales growth.

Household Cleaning Segment

Revenues for the Household Cleaning segment decreased $5.3 million, or 6.9%, during the nine months ended December 31, 2011 versus the nine months ended December 31, 2010. Weaker Comet sales were partially offset by stronger performance with Spic and Span and Chore Boy. Comet revenues decreased primarily due to lower consumer demand for non-abrasive products. Spic and Span and Chore Boy revenues continued to benefit from increased promotional activity, expanded distribution and consumer demand for Spic and Span sprays and Chore Boy copper scrubbers in the nine months ended December 31, 2011 versus the nine months ended December 31, 2010.

Gross Profit



	Nine Months Ended December 31,
	2011			2010			Increase
(In thousands, except percentages)	Gross Profit		%	Gross Profit		%	(Decrease)			%
Gross Profit
OTC Healthcare	$	138,066	58.7	$	98,543	60.4	$	39,523		40.1
Household Cleaning	20,830		29.0	26,030		33.7	(5,200		)	(20.0	)

	$	158,896	51.7	$	124,573	51.9	$	34,323		27.6

Gross profit for the nine months ended December 31, 2011 increased $34.3 million, or 27.6%, when compared with the nine months ended December 31, 2010. As a percent of total revenues, gross profit decreased from 51.9% in the nine months ended December 31, 2010 to 51.7% in the nine months ended December 31, 2011. The Blacksmith and Dramamine brands provided an increase in gross profit of $33.9 million, while our legacy core OTC Healthcare brands increased gross profit by $4.5 million. Gross profit in the prior year nine month period included a $3.5 million inventory step-up charge related to the Blacksmith acquisition. These increases were partially offset by decreases in gross profit from our Household Cleaning segment. The decrease in gross profit as a percent of revenues was primarily due to the lower revenues and resulting gross margin from the Household Cleaning segment and the realization of lower margins from the acquired Blacksmith products.

-40-

OTC Healthcare Segment

Gross profit for the OTC Healthcare segment increased $39.5 million, or 40.1%, during the nine months ended December 31, 2011 versus the nine months ended December 31, 2010. As a percent of OTC Healthcare revenues, gross profit decreased from 60.4% during the nine months ended December 31, 2010 to 58.7% during the nine months ended December 31, 2011. The decrease in gross profit percentage was primarily the result of lower margins from the acquired Blacksmith products, partially offset by the higher margins from the acquired Dramamine brand and slightly higher margins from our legacy OTC Healthcare brands.

Household Cleaning Segment

Gross profit for the Household Cleaning segment decreased by $5.2 million, or 20.0%, during the nine months ended December 31, 2011 versus the nine months ended December 31, 2010. As a percent of Household Cleaning revenue, gross profit decreased from 33.7% during the nine months ended December 31, 2010 to 29.0% during the nine months ended December 31, 2011. The decrease in gross profit percentage was primarily the result of the decreased revenue and resulting margin reduction in our Comet brand.

Contribution Margin



	Nine Months Ended December 31,
	2011			2010
(In thousands, except percentages)	Contribution Margin		%	Contribution Margin		%	Increase (Decrease)			%
Contribution Margin
OTC Healthcare	$	103,320	43.9	$	74,625	45.8	$	28,695		38.5
Household Cleaning	16,996		23.7	21,173		27.5	(4,177		)	(19.7	)

	$	120,316	39.2	$	95,798	39.9	$	24,518		25.6

Contribution margin, a non-GAAP financial measure which is defined as gross profit less advertising and promotional expenses, increased $24.5 million, or 25.6%, during the nine months ended December 31, 2011 versus the nine months ended December 31, 2010. The contribution margin increase was primarily the result of the higher gross profit previously discussed, offset by higher advertising and promotional spending and lower Household Cleaning sales and resulting gross profit. The acquired Blacksmith and Dramamine brands added $25.5 million and our legacy OTC Healthcare brands added $3.2 million to contribution margin. These increases were partially offset by a $4.2 million decline in contribution margin in our Household Cleaning brands due primarily to lower sales volumes and resulting in a reduction of gross margins.

OTC Healthcare Segment

Contribution margin for the OTC Healthcare segment increased $28.7 million, or 38.5%, during the nine months ended December 31, 2011 versus the nine months ended December 31, 2010. The contribution margin increase was the result of the gross profit as previously discussed and the $25.5 million contribution margin increase primarily related to the acquired Blacksmith and Dramamine products. Advertising and promotional spending increased $10.8 million, or 45.3%, primarily due to the acquired Blacksmith and Dramamine products and, to a lesser extent, to increased investment in the legacy core OTC Healthcare brands.

Household Cleaning Segment

Contribution margin for the Household Cleaning segment decreased $4.2 million, or 19.7%, during the nine months ended December 31, 2011 versus the nine months ended December 31, 2010. The contribution margin decrease was the result of the decrease in gross profit as previously discussed, partially offset by a $1.0 million, or 21.1%, decrease in advertising and promotional spending. The decrease in advertising and promotional spending primarily related to the timing of Household Cleaning promotional activities that occurred in 2010.

General and Administrative

General and administrative expenses were $32.4 million for the nine months ended December 31, 2011 versus $30.9 million for the nine months ended December 31, 2010. The increase in general and administrative expenses was primarily due to the incurrence of $5.7 million of acquisition related costs, higher legal costs of $1.2 million, higher personnel costs of $0.7 million and infrastructure costs of $0.5 million in the current year period, offset by the $6.9 million of transaction and severance costs associated with the Blacksmith acquisition in the prior year period.

Depreciation and Amortization

Depreciation and amortization expense was $7.7 million for the nine months ended December 31, 2011 and $7.3 million for the nine months ended December 31, 2010.

-41-

Interest Expense

Net interest expense was $25.0 million during the nine months ended December 31, 2011 versus $18.5 million during the nine months ended December 31, 2010. The increase in interest expense was primarily the result of a higher level of indebtedness outstanding related to the Blacksmith and Dramamine acquisitions. The cost of borrowing increased slightly from 5.9% for the nine months ended December 31, 2010 to 7.2% for the nine months ended December 31, 2011, while the average indebtedness outstanding increased from $418.8 million during the nine months ended December 31, 2010 to $463.0 million during the nine months ended December 31, 2011 due to increased debt issued for the Blacksmith and Dramamine acquisitions.

Gain on Settlement

On June 15, 2011, we received a settlement payment of $8.0 million in the resolution of a pending litigation matter. We incurred costs of $2.9 million in pursuing this matter. Therefore, during the nine months ended December 31, 2011, we recorded a pre-tax gain on settlement of $5.1 million net of costs incurred, which is included in other (income) expense, as this gain did not relate to our ongoing operations.

Income Taxes

The provision for income taxes during the nine months ended December 31, 2011 was $23.1 million versus $15.9 million during the nine months ended December 31, 2010. The effective tax rate during the nine months ended December 31, 2011 and December 31, 2010 was 38.3% and 41.2%, respectively. The decrease in the effective tax rate is primarily due to $0.8 million of non-deductible transaction expenses related to the Blacksmith acquisition and a $0.3 million charge for our deferred state tax rate incurred in the prior year period. The estimated effective tax rate for the remaining quarter of the year ending March 31, 2012 is expected to be 38.7%, excluding the impact of discrete items that may occur.

Liquidity and Capital Resources

Liquidity

We have financed and expect to continue to finance our operations with a combination of borrowings and funds generated from operations. Our principal uses of cash are for operating expenses, debt service, acquisitions, working capital and capital expenditures. On March 24, 2010, we entered into a new $150.0 million Senior Secured Term Loan Facility with a maturity date of March 24, 2016 (the "2010 Senior Term Loan"), a $30.0 million Senior Secured Revolving Credit Facility with a maturity date of March 24, 2015 (the "2010 Revolving Credit Facility" and collectively with the 2010 Senior Term Loan, the "Credit Agreement") and issued Senior Notes of $150.0 million that bear interest at 8.25% with a maturity date of April 1, 2018 (the "2010 Senior Notes"). In November 2010, we issued an additional $100.0 million of 8.25% Senior Notes due in 2018 and borrowed an additional $115.0 million term loan under the Credit Agreement. In addition, in November 2010, we amended our Credit Agreement to increase our borrowing capacity under the 2010 Revolving Credit Facility by $10.0 million to $40.0 million. The proceeds from the preceding transactions, in addition to cash that was on hand, were used to purchase, redeem or otherwise retire all of the previously issued senior subordinated notes, to repay all amounts under our former credit facility and terminate the associated credit agreement, and to fund the Blacksmith and Dramamine acquisitions.

Operating Activities

Net cash provided by operating activities was $48.0 million for the nine months ended December 31, 2011 compared to $61.7 million for the nine months ended December 31, 2010. The $13.7 million decrease in net cash provided by operating activities was primarily due to higher working capital requirements, primarily related to higher receivables and inventory levels associated with the Blacksmith and Dramamine acquisitions and to higher interest payments following our additional financing in November 2010 and higher incentive compensation payments in the current year period resulting from increased company performance in 2011 versus 2010. These decreases were partially offset by higher company performance in 2012 versus 2011, including a one-time gain associated with the legal settlement in the current year period as discussed in Note 20 to the Consolidated Financial Statements in this Quarterly Report on Form 10-Q.

Consistent with the nine months ended December 31, 2010, our cash flow from operations in the nine months ended December 31, 2011 exceeded net income due to the substantial non-cash charges related to depreciation and amortization, increases in deferred income tax liabilities resulting from differences in the amortization of intangible assets and goodwill for income tax purposes, the amortization of certain deferred financing costs and debt discount, and stock-based compensation costs.

Investing Activities

Net cash provided by investing activities was $0.8 million for the nine months ended December 31, 2011 compared to $198.3 million of net cash used in investing activities for the nine months ended December 31, 2010. Net cash provided by investing activities for the nine months ended December 31, 2011 was primarily the result of the escrow receipt of a $1.2 million working capital adjustment awarded to us, which was related to the purchase price of Blacksmith as discussed in Note 2 to the Consolidated Financial Statements in this Quarterly Report on Form 10-Q. Net cash used in investing activities for the nine month period ended

-42-

December 31, 2010 was primarily the result of the Blacksmith acquisition, partially offset by proceeds received from the Cutex divestiture.

Financing Activities

Net cash used in financing activities was $57.7 million for the nine months ended December 31, 2011 compared to $178.8 million of net cash provided by financing activities for the nine months ended December 31, 2010. During the nine months ended December 31, 2011, we repaid $58.0 million of our outstanding debt. This decreased our outstanding indebtedness to $434.0 million at December 31, 2011 from $492.0 million at March 31, 2011. During the nine month period ended December 31, 2010, we issued an additional $100.0 million of 8.25% Senior Notes due in 2018 and borrowed $115.0 million under the Credit Agreement, which was partially offset by the redemption of the remaining $28.1 million of our Senior Subordinated Notes due in 2012 that bore interest at 9.25%, and payment of the required principal amount on the 2010 Senior Term Loan of $0.8 million plus an additional principal amount of $3.8 million.



	Nine Months Ended December 31,
(In thousands)	2011			2010
Cash provided by (used in):
Operating Activities	$	47,993		$	61,659
Investing Activities	842			(198,327		)
Financing Activities	(57,699		)	178,837

Capital Resources

On March 24, 2010, we retired our Senior Secured Term Loan Facility, which had a maturity date of April 6, 2011. In addition, on March 24, 2010, we repaid a portion and, on April 15, 2010, redeemed in full the remaining outstanding indebtedness under our previously outstanding Senior Subordinated Notes due in 2012, which bore interest at 9.25% with a maturity date of April 15, 2012. In March 2010, we entered into the Credit Agreement and issued the 2010 Senior Notes. This debt refinancing improved our liquidity position by increasing our borrowing capacity under our senior secured term loan and revolving credit facilities and extending the maturities of our indebtedness. However, under certain circumstances, contractual and legal restrictions, as well as the financial condition and operating requirements of our subsidiaries, could limit Prestige Brands, Inc.'s ability to obtain cash from our subsidiaries for the purpose of meeting our debt service obligations, including the payment of principal and interest on the 2010 Senior Notes. Additionally, we believe that the new debt better positions us to pursue acquisitions as part of our growth strategy.

The 2010 Senior Term Loan included a discount to the lenders of $1.8 million, resulting in our receipt of net proceeds of $148.2 million. The 2010 Senior Notes were issued at an aggregate face value of $150.0 million with a discount to note-holders of $2.2 million and net proceeds to us of $147.8 million. The discount was offered to improve the yield to maturity to lenders reflective of market conditions at the time of the offering. In addition to the discount, we incurred $7.3 million of costs primarily related to fees of bank arrangers and legal advisors, of which $6.6 million was capitalized as deferred financing costs and $0.7 million was expensed. The deferred financing costs are being amortized over the term of the loan and notes.

In connection with the acquisition of Blacksmith, on November 1, 2010, we amended our existing debt agreements and increased the amount borrowed thereunder. Specifically, on November 1, 2010, we amended our Credit Agreement in order to allow us to (i) borrow an additional $115.0 million as an incremental term loan, with the same maturity date and other terms and conditions as the 2010 Senior Term Loan and (ii) increase our borrowing capacity under our 2010 Revolving Credit Facility by $10.0 million to $40.0 million. On November 1, 2010, we also issued an additional $100.0 million of 2010 Senior Notes.

As of December 31, 2011, we had an aggregate of $434.0 million of outstanding indebtedness, which consisted of the following:


•	$184.0 million of borrowings under the 2010 Senior Term Loan, and


•	$250.0 million of 2010 Senior Notes.

We had $40.0 million of borrowing capacity under our 2010 Revolving Credit Facility as of December 31, 2011, as well as incremental borrowing capacity of $75.0 million under our 2010 Senior Term Loan.

The 2010 Senior Term Loan bears interest at floating rates, based on either the prime rate or, at our option, the LIBOR rate plus an applicable margin. The LIBOR rate option contains a floor rate of 1.5%. At December 31, 2011, an aggregate of $184.0 million was outstanding under the Credit Agreement, which carried an interest rate of 4.75%.

-43-

The Credit Agreement, including the 2010 Senior Term Loan, contains various financial covenants, including provisions that require us to maintain certain leverage and interest coverage ratios and not to exceed annual capital expenditures of $3.0 million. The Credit Agreement and the Indenture governing the 2010 Senior Notes also contain provisions that accelerate our indebtedness upon the occurrence of certain events and restrict us from undertaking specified corporate actions, including asset dispositions, acquisitions, payments of dividends and other specified payments, repurchasing our equity securities in the public markets, incurrence of indebtedness, creation of liens, making loans and investments and transactions with affiliates. Specifically, we must:

•

Have a leverage ratio of less than 4.00 to 1.0 for the quarter ended December 31, 2011 (defined as, with certain adjustments, the ratio of our consolidated indebtedness as of the last day of the fiscal quarter to our trailing twelve month consolidated net income before interest, taxes, depreciation, amortization, non-cash charges, and certain other items (“EBITDA”)). Our leverage ratio requirement decreases over time to 3.50 to 1.0 for the quarter ending March 31, 2014 and remains level thereafter; and


•	Have an interest coverage ratio of greater than 3.00 to 1.0 for the quarter ended December 31, 2011 (defined as, with certain adjustments, the ratio of our consolidated EBITDA to our trailing twelve month consolidated cash interest expense). Our interest coverage requirement increases over time to 3.25 to 1.0 for the quarter ending March 31, 2013 and remains level thereafter.

At December 31, 2011, we were in compliance with the applicable financial and restrictive covenants under the Credit Agreement and the Indenture governing the 2010 Senior Notes. Additionally, management anticipates that in the normal course of operations, we will be in compliance with the financial and restrictive covenants during the ensuing year. During the nine months ended December 31, 2011, we made voluntary principal payments against outstanding indebtedness of $58.0 million in excess of required payments under the Credit Agreement governing the 2010 Senior Term Loan. In accordance with the Credit Agreement, such payments were applied against the first four required principal payments, and any remaining principal payments were applied ratably toward the remaining required principal payments. As such, we do not have a required principal payment until the 2010 Senior Term Loan matures in 2016.

On January 31, 2012, in connection with the completed acquisition of the GSK Brands I and the anticipated acquisition of GSK Brands II, as discussed above, we repaid the 2010 Senior Term Loan and entered into a New Senior Secured Credit Facility which consists of (i) a $660.0 million term loan facility (“New Term Loan Facility”) with a seven-year maturity, and (ii) a $50.0 million asset-based revolving credit facility (“New ABL Revolving Credit Facility”) with a five-year maturity. In addition, we have agreed to secure our 2010 Senior Notes ratably with the New Term Loan Facility.

Borrowings under our New Senior Secured Credit Facility bear interest at a rate per annum of (i) with respect to term loans, at our option, at the Eurocurrency Rate (as defined in the agreement) plus 4.00% or Base Rate (as defined in the agreement) plus 3.00%, (ii) with respect to revolving loans, at our option, at the Eurocurrency Rate plus a range of 1.75% to 2.25% depending on Excess Availability (as defined in the agreement) or Base Rate plus a range of 0.75% to 1.25% depending on Excess Availability, and (iii) with respect to swing line loans, Base Rate plus a range of 0.75% to 1.25% depending on Excess Availability.

We will be required to make quarterly payments each equal to 0.25% of the original principal amount of the term loan made on the closing date, with the balance expected to be due on the seventh anniversary of the closing date.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements or financing activities with special-purpose entities.

Inflation

Inflationary factors such as increases in the costs of raw materials, packaging materials, purchased product and overhead may adversely affect our operating results. Although we do not believe that inflation has had a material impact on our financial condition or results from operations for the periods referred to above, a high rate of inflation in the future could have a material adverse effect on our financial condition or results from operations. The recent volatility in crude oil prices has had an adverse impact on transportation costs, as well as certain petroleum based raw materials and packaging material. Although we make efforts to minimize the impact of inflationary factors, including raising prices to our customers, a high rate of pricing volatility associated with crude oil supplies may continue to have an adverse effect on our operating results.

-44-

Critical Accounting Policies and Estimates

Our significant accounting policies are described in the notes to the unaudited financial statements included elsewhere in this Quarterly Report on Form 10-Q, as well as in our Annual Report on Form 10-K for the fiscal year ended March 31, 2011. While all significant accounting policies are important to our Consolidated Financial Statements, certain of these policies may be viewed as being critical. Such policies are those that are both most important to the portrayal of our financial condition and results of operations and require our most difficult, subjective and complex estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, or the related disclosure of contingent assets and liabilities. These estimates are based upon our historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different conditions. The most critical accounting estimates are described below:

Revenue Recognition

We recognize revenue when the following revenue recognition criteria are met: (i) persuasive evidence of an arrangement exists, (ii) the product has been shipped and the customer takes ownership and assumes the risk of loss, (iii) the selling price is fixed or determinable, and (iv) collection of the resulting receivable is reasonably assured. We have determined that these criteria are met and the transfer of risk of loss generally occurs when product is received by the customer and, accordingly, recognize revenue at that time. Provision is made for estimated discounts related to customer payment terms and estimated product returns at the time of sale based on our historical experience.

As is customary in the consumer products industry, we participate in the promotional programs of our customers to enhance the sale of our products. The cost of these promotional programs is recorded as advertising and promotional expenses or as a reduction of sales based upon the nature of such items and the applicable accounting guidance. Such costs vary from period to period based on the actual number of units sold during a finite period of time. We estimate the cost of such promotional programs at their inception based on historical experience and current market conditions and reduce sales by such estimates. These promotional programs consist of direct-to-consumer incentives, such as coupons and temporary price reductions, as well as incentives to our customers, such as allowances for new distribution, including slotting fees, and cooperative advertising. Direct reimbursements of advertising costs are reflected as a reduction of advertising costs in the periods in which the reimbursement criteria are achieved. We do not provide incentives to customers for the acquisition of product in excess of normal inventory quantities, because such incentives increase the potential for future returns, as well as reduce sales in the subsequent fiscal periods.

Estimates of costs of promotional programs are based on (i) historical sales experience, (ii) the current promotional offering, (iii) forecasted data, (iv) current market conditions, and (v) communication with customer purchasing/marketing personnel. At the completion of the promotional program, the estimated amounts are adjusted to actual results. Our related promotional expense for the fiscal year ended March 31, 2011 was $21.3 million. For the three and nine months ended December 31, 2011, our related promotional expense was $7.9 million and $20.2 million, respectively. We believe that the estimation methodologies employed, combined with the nature of the promotional campaigns, make the likelihood remote that our obligation would be misstated by a material amount. However, for illustrative purposes, had we underestimated the promotional program rate by 10% for the fiscal year ended March 31, 2011, our sales and operating income would have been adversely affected by approximately $2.1 million. Net income would have been adversely affected by approximately $1.3 million. Similarly, had we underestimated the promotional program rate by 10% for the three and nine months ended December 31, 2011, our sales and operating income would have been adversely affected by approximately $0.8 million and $2.1 million, respectively. Net income would have been adversely affected by approximately $0.5 million and $1.3 million for the three and nine months ended December 31, 2011, respectively.

We also periodically run coupon programs in Sunday newspaper inserts, on our product website or as on-package instant redeemable coupons. We utilize a national clearing house to process coupons redeemed by customers. At the time a coupon is distributed, a provision is made based upon historical redemption rates for that particular product, information provided as a result of the clearing house's experience with coupons of similar dollar value, the length of time the coupon is valid, and the seasonality of the coupon drop, among other factors. During the fiscal year ended March 31, 2011, we had 46 coupon events. The amount recorded against revenues and accrued for these events during the year was $3.9 million. Cash settlement of coupon redemptions during the year was $3.1 million. During the three months ended December 31, 2011, we had 30 coupon events, and during the nine months ended December 31, 2011, we had 86 coupon events. The amount recorded against revenue and accrued for these events during the three and nine months ended December 31, 2011 was $1.9 million and $5.1 million, respectively. Cash settlement of coupon redemptions during the three and nine months ended December 31, 2011 was $1.1 million and $4.1 million, respectively.

Allowances for Product Returns

Due to the nature of the consumer products industry, we are required to estimate future product returns. Accordingly, we record an estimate of product returns concurrent with the recording of sales. Such estimates are made after analyzing (i) historical return rates, (ii) current economic trends, (iii) changes in customer demand, (iv) product acceptance, (v) seasonality of our product

-45-

offerings, and (vi) the impact of changes in product formulation, packaging and advertising.

We construct our returns analysis by looking at the previous year's return history for each brand. Subsequently, each month, we estimate our current return rate based upon an average of the previous six months' return rate and review that calculated rate for reasonableness, giving consideration to the other factors described above. Our historical return rate has been relatively stable; for example, for the fiscal years ended March 31, 2011, 2010 and 2009, returns represented 2.7%, 3.8% and 3.7%, respectively, of gross sales. For the three and nine months ended December 31, 2011, product returns represented 2.4% and 3.0% of gross sales, respectively. At December 31, 2011 and March 31, 2011, the allowance for sales returns was $3.7 million and $5.2 million, respectively.

While we utilize the methodology described above to estimate product returns, actual results may differ materially from our estimates, causing our future financial results to be adversely affected. Among the factors that could cause a material change in the estimated return rate would be significant unexpected returns with respect to a product or products that comprise a significant portion of our revenues. Based upon the methodology described above and our actual returns experience, management believes the likelihood of such an event remains remote. As noted, over the last three years our actual product return rate has stayed within a range of 2.4% to 3.8% of gross sales. A hypothetical increase of 0.1% in our estimated return rate as a percentage of gross sales would have adversely affected our reported sales and operating income for the fiscal year ended March 31, 2011 by approximately $0.4 million. Net income would have been adversely affected by approximately $0.2 million. A hypothetical increase of 0.1% in our estimated return rate as a percentage of gross sales for the three and nine months ended December 31, 2011 would have adversely affected our reported sales and operating income by approximately $0.1 million and $0.4 million, respectively, while our net income would have been adversely affected by approximately $0.1 million and $0.2 million for each of the periods, respectively.

Lower of Cost or Market for Obsolete and Damaged Inventory

We value our inventory at the lower of cost or market value. Accordingly, we reduce our inventories for the diminution of value resulting from product obsolescence, damage or other issues affecting marketability, equal to the difference between the cost of the inventory and its estimated market value. Factors utilized in the determination of estimated market value include (i) current sales data and historical return rates, (ii) estimates of future demand, (iii) competitive pricing pressures, (iv) new product introductions, (v) product expiration dates, and (vi) component and packaging obsolescence.

Many of our products are subject to expiration dating. As a general rule, our customers will not accept goods with expiration dating of less than 12 months from the date of delivery. To monitor this risk, management utilizes a detailed compilation of inventory with expiration dating between zero and 15 months and reserves for 100% of the cost of any item with expiration dating of 12 months or less. Inventory obsolescence costs charged to operations were $0.2 million for the fiscal year ended March 31, 2011, while for the three and nine months ended December 31, 2011, we recorded obsolescence costs of $0.5 million and $2.2 million, respectively. A 1.0% increase in our allowance for obsolescence at March 31, 2011 would have adversely affected our reported operating income and net income for the fiscal year ended March 31, 2011 by approximately $0.4 million and $0.2 million, respectively. Similarly, a 1.0% increase in our obsolescence allowance at December 31, 2011 would have adversely affected our reported operating income and net income by approximately $0.5 million and $0.3 million, respectively, for each of the three and nine months ended December 31, 2011.

Allowance for Doubtful Accounts

In the ordinary course of business, we grant non-interest bearing trade credit to our customers on normal credit terms. We maintain an allowance for doubtful accounts receivable, which is based upon our historical collection experience and expected collectability of the accounts receivable. In an effort to reduce our credit risk, we (i) establish credit limits for all of our customer relationships, (ii) perform ongoing credit evaluations of our customers' financial condition, (iii) monitor the payment history and aging of our customers' receivables, and (iv) monitor open orders against an individual customer's outstanding receivable balance.

We establish specific reserves for those accounts that file for bankruptcy, have no payment activity for 180 days, or have reported major negative changes to their financial condition. The allowance for bad debts amounted to 1.1% and 0.9% of accounts receivable at December 31, 2011 and March 31, 2011, respectively. Bad debt expense for the fiscal year ended March 31, 2011 was $0.2 million, while during each of the three and nine months ended December 31, 2011, we recorded bad debt expense of less than $0.1 million and $0.2 million, respectively.

While management believes that it is diligent in its evaluation of the adequacy of the allowance for doubtful accounts, an unexpected event, such as the bankruptcy filing of a major customer, could have an adverse effect on our future financial results. A hypothetical increase of 0.1% in our bad debt expense as a percentage of sales during the fiscal year ended March 31, 2011 would have resulted in a decrease in reported operating income of approximately $0.3 million and a decrease in our reported net income of approximately $0.2 million. Similarly, a 0.1% increase in our bad debt expense as a percentage of sales for the three and nine months ended

-46-

December 31, 2011 would have resulted in a decrease in reported operating income of $0.1 million and $0.3 million, respectively, and a decrease in our reported net income of less than $0.1 million and $0.2 million, respectively.

Valuation of Intangible Assets and Goodwill

Goodwill and intangible assets amounted to $932.9 million and $941.3 million at December 31, 2011 and March 31, 2011, respectively. At December 31, 2011, goodwill and intangible assets were apportioned among our two operating segments as follows:



(In thousands)	OTC Healthcare		Household Cleaning		Consolidated

Goodwill	$	146,307	$	7,389	$	153,696

Intangible assets
Indefinite-lived	568,664		119,820		688,484
Finite-lived	60,666		30,092		90,758
	629,330		149,912		779,242

	$	775,637	$	157,301	$	932,938

Our Chloraseptic, Clear Eyes, Compound W, Dramamine, Efferdent, Luden's and PediaCare brands comprise the majority of the value of the intangible assets within the OTC Healthcare segment. The Chore Boy, Comet, and Spic and Span brands comprise substantially all of the intangible asset value within the Household Cleaning segment.

Goodwill and intangible assets comprise substantially all of our assets. Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed in a purchase business combination. Intangible assets generally represent our trademarks, brand names and patents. When we acquire a brand, we are required to make judgments regarding the value assigned to the associated intangible assets, as well as their respective useful lives. Management considers many factors both prior to and after the acquisition of an intangible asset in determining the value, as well as the useful life, assigned to each intangible asset that we acquire or continue to own and promote. The most significant factors are:


•	Brand History

A brand that has been in existence for a long period of time (e.g., 25, 50 or 100 years) generally warrants a higher valuation and longer life (sometimes indefinite) than a brand that has been in existence for a very short period of time. A brand that has been in existence for an extended period of time generally has been the subject of considerable investment by its previous owner(s) to support product innovation and advertising and promotion.


•	Market Position

Consumer products that rank number one or two in their respective market generally have greater name recognition and are known as quality product offerings, which warrant a higher valuation and longer life than products that lag in the marketplace.


•	Recent and Projected Sales Growth

Recent sales results present a snapshot as to how the brand has performed in the most recent time periods and represent another factor in the determination of brand value. In addition, projected sales growth provides information about the strength and potential longevity of the brand. A brand that has both strong current and projected sales generally warrants a higher valuation and a longer life than a brand that has weak or declining sales. Similarly, consideration is given to the potential investment, in the form of advertising and promotion, that is required to reinvigorate a brand that has fallen from favor.


•	History of and Potential for Product Extensions

Consideration also is given to the product innovation that has occurred during the brand's history and the potential for continued product innovation that will determine the brand's future. Brands that can be continually enhanced by new product offerings generally warrant a higher valuation and longer life than a brand that has always “followed the leader”.

After consideration of the factors described above, as well as current economic conditions and changing consumer behavior, management prepares a determination of the intangible assets' values and useful lives based on its analysis. Under accounting guidelines, goodwill is not amortized, but must be tested for impairment annually, or more frequently if an event occurs or

-47-

circumstances change that would more likely than not reduce the fair value of the reporting unit below the carrying amount. In a similar manner, indefinite-lived assets are no longer amortized. They are also subject to an annual impairment test, or more frequently if events or changes in circumstances indicate that the asset may be impaired. Additionally, at each reporting period an evaluation must be made to determine whether events and circumstances continue to support an indefinite useful life. Intangible assets with finite lives are amortized over their respective estimated useful lives and must also be tested for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable and exceeds its fair value.

On an annual basis, during the fourth fiscal quarter of each year, or more frequently if conditions indicate that the carrying value of the asset may not be recovered, management performs a review of both the values and, if applicable, useful lives assigned to goodwill and intangible assets and tests for impairment.

We report goodwill and indefinite-lived intangible assets in two operating segments: OTC Healthcare and Household Cleaning. We identify our reporting units in accordance with the Financial Accounting Standards Board ("FASB") ASC Subtopic 280-10, which is at the brand level, and one level below the operating segment level. The carrying value and fair value for intangible assets and goodwill for a reporting unit are calculated based on the key assumptions and valuation methodologies previously discussed. As a result, any material changes to these assumptions could require us to record additional impairment in the future.

Goodwill

As of March 31, 2011, we had nine reporting units with goodwill. The aggregate fair value exceeded the carrying value by 30.2%. No individual reporting unit's fair value exceeded its carrying value by less than 5.0%, except for two reporting units in the OTC Healthcare segment. One reporting unit's fair value exceeded the carrying value by 2.1% and the associated goodwill amounted to $2.4 million. The second reporting unit exceeded the carrying value by 4.8% and the associated goodwill amounted to $12.6 million.

As part of our annual test for impairment of goodwill, management estimates the discounted cash flows of each reporting unit, which is at the brand level, and one level below the operating segment level, to estimate their respective fair values. In performing this analysis, management considers the same types of information as listed below with regard to finite-lived intangible assets. In the event that the carrying amount of the reporting unit exceeds the fair value, management would then be required to allocate the estimated fair value of the assets and liabilities of the reporting unit as if the unit was acquired in a business combination, thereby revaluing the carrying amount of goodwill. Future events, such as competition, technological advances and reductions in advertising support for our trademarks and trade names, could cause subsequent evaluations to utilize different assumptions.

Indefinite-Lived Intangible Assets

In a manner similar to finite-lived intangible assets, at each reporting period, management analyzes current events and circumstances to determine whether the indefinite life classification for a trademark or trade name continues to be valid. If circumstances warrant a change to a finite life, the carrying value of the intangible asset would then be amortized prospectively over the estimated remaining useful life.

Management tests the indefinite-lived intangible assets for impairment by comparing the carrying value of the intangible asset to its estimated fair value. Since quoted market prices are seldom available for trademarks and trade names such as ours, we utilize present value techniques to estimate fair value. Accordingly, management's projections are utilized to assimilate all of the facts, circumstances and expectations related to the trademark or trade name and estimate the cash flows over its useful life. In performing this analysis, management considers the same types of information as listed below with regard to finite-lived intangible assets. Once that analysis is completed, a discount rate is applied to the cash flows to estimate fair value. In a manner similar to goodwill, future events, such as competition, technological advances and reductions in advertising support for our trademarks and trade names, could cause subsequent evaluations to utilize different assumptions.

Finite-Lived Intangible Assets

As mentioned above, when events or changes in circumstances indicate the carrying value of the assets may not be recoverable, management performs a review to ascertain the impact of events and circumstances on the estimated useful lives and carrying values of our trademarks and trade names. In connection with this analysis, management:


•	Reviews period-to-period sales and profitability by brand;


•	Analyzes industry trends and projects brand growth rates;


•	Prepares annual sales forecasts;


•	Evaluates advertising effectiveness;


•	Analyzes gross margins;


•	Reviews contractual benefits or limitations;


•	Monitors competitors' advertising spend and product innovation;

-48-


•	Prepares projections to measure brand viability over the estimated useful life of the intangible asset; and


•	Considers the regulatory environment, as well as industry litigation.

If analysis of any of the aforementioned factors warrants a change in the estimated useful life of the intangible asset, management will reduce the estimated useful life and amortize the carrying value prospectively over the shorter remaining useful life. Management's projections are utilized to assimilate all of the facts, circumstances and expectations related to the trademark or trade name and estimate the cash flows over its useful life. In the event that the long-term projections indicate that the carrying value is in excess of the undiscounted cash flows expected to result from the use of the intangible assets, management is required to record an impairment charge. Once that analysis is completed, a discount rate is applied to the cash flows to estimate fair value. The impairment charge is measured as the excess of the carrying amount of the intangible asset over fair value, as calculated using the discounted cash flow analysis. Future events, such as competition, technological advances and reductions in advertising support for our trademarks and trade names, could cause subsequent evaluations to utilize different assumptions.

Impairment Analysis

We estimate the fair value of our intangible assets and goodwill using a discounted cash flow method. This discounted cash flow methodology is a widely-accepted valuation technique to estimate fair value utilized by market participants in the transaction evaluation process and has been applied consistently. In addition, we considered our market capitalization at March 31, 2011, as compared to the aggregate fair values of our reporting units, to assess the reasonableness of our estimates pursuant to the discounted cash flow methodology. As a result of our analysis, we did not record an impairment charge during the three months ended March 31, 2011.

The discount rate utilized in the analyses, as well as future cash flows, may be influenced by such factors as changes in interest rates and rates of inflation. Additionally, should the related fair values of goodwill and intangible assets continue to be adversely affected as a result of declining sales or margins caused by competition, changing consumer preferences, technological advances or reductions in advertising and promotional expenses, we may be required to record additional impairment charges in the future. However, no impairment charge was recorded during the three and nine months ended December 31, 2011.

Stock-Based Compensation

The Compensation and Equity topic of the FASB ASC requires us to measure the cost of services to be rendered based on the grant-date fair value of an equity award. Compensation expense is to be recognized over the period during which an employee is required to provide service in exchange for the award, generally referred to as the requisite service period. Information utilized in the determination of fair value includes the following:


•	Type of instrument (i.e., restricted shares vs. an option, warrant or performance shares);


•	Strike price of the instrument;


•	Market price of our common stock on the date of grant;


•	Discount rates;


•	Duration of the instrument; and


•	Volatility of our common stock in the public market.

Additionally, management must estimate the expected attrition rate of the recipients to enable it to estimate the amount of non-cash compensation expense to be recorded in our financial statements. While management uses diligent analysis to estimate the respective variables, a change in assumptions or market conditions, as well as changes in the anticipated attrition rates, could have a significant impact on the future amounts recorded as non-cash compensation expense. We recorded non-cash compensation expense of $0.7 million and $1.1 million for the three months ended December 31, 2011 and 2010, respectively, and non-cash compensation expense of $2.4 million and $2.8 million for the nine months ended December 30, 2011 and 2010, respectively.

Loss Contingencies

Loss contingencies are recorded as liabilities when it is probable that a liability has been incurred and the amount of such loss is reasonably estimable. Contingent losses are often resolved over longer periods of time and involve many factors including:


•	Rules and regulations promulgated by regulatory agencies;


•	Sufficiency of the evidence in support of our position;


•	Anticipated costs to support our position; and


•	Likelihood of a positive outcome.

-49-

Recent Accounting Pronouncements

In June 2011, the FASB issued guidance regarding presentation of comprehensive income. Under the ASC Comprehensive Income topic, entities are allowed the option to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements. In both choices, an entity is required to present each component of net income along with total net income, each component of other comprehensive income along with a total for other comprehensive income, and a total amount for comprehensive income. This guidance eliminates the option to present the components of other comprehensive income as part of the statement of changes in stockholders' equity. This guidance does not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income.

-50-

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”), including, without limitation, information within Management's Discussion and Analysis of Financial Condition and Results of Operations. The following cautionary statements are being made pursuant to the provisions of the PSLRA and with the intention of obtaining the benefits of the “safe harbor” provisions of the PSLRA. Although we believe that our expectations are based on reasonable assumptions, actual results may differ materially from those in the forward-looking statements.

Forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q. Except as required under federal securities laws and the rules and regulations of the SEC, we do not have any intention to update any forward-looking statements to reflect events or circumstances arising after the date of this Quarterly Report on Form 10-Q, whether as a result of new information, future events or otherwise. As a result of these risks and uncertainties, readers are cautioned not to place undue reliance on forward-looking statements included in this Quarterly Report on Form 10-Q or that may be made elsewhere from time to time by, or on behalf of, us. All forward-looking statements attributable to us are expressly qualified by these cautionary statements.

These forward-looking statements generally can be identified by the use of words or phrases such as “believe,” “anticipate,” “expect,” “estimate,” “project,” “will be,” “will continue,” “will likely result,” or other similar words and phrases. Forward-looking statements and our plans and expectations are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, and our business in general is subject to such risks. For more information, see “Risk Factors” contained in Part I, Item 1A. of our Annual Report on Form 10-K for our fiscal year ended March 31, 2011. In addition, our expectations or beliefs concerning future events involve risks and uncertainties, including, without limitation:


•	The high level of competition from branded and private label competitors in our industry;


•	Our dependence on a limited number of customers for a large portion of our sales;


•	General economic conditions affecting our products and their respective markets;


•	Changing consumer trends or pricing pressures which may cause us to lower our prices;


•	Our dependence on third-party manufacturers to produce the products we sell;


•	Price increases for raw materials, labor, energy and transportation costs;


•	Disruptions in our distribution center;


•	Acquisitions, dispositions or other strategic transactions (including the recent acquisition of OTC healthcare brands from GlaxoSmithKline plc) diverting managerial resources, or incurrence of additional liabilities or integration problems associated with such transactions;


•	Regulatory matters governing our industry;


•	Product liability claims, recalls and related negative publicity;


•	Our ability to protect our intellectual property rights;


•	Our dependence on third parties for intellectual property relating to some of the products we sell;


•	Our assets being comprised virtually entirely of goodwill and intangibles;


•	Our dependence on key personnel;


•	The costs associated with any adverse judgments rendered in any pending litigation or arbitration;


•	Our level of indebtedness, and possible inability to service our debt;


•	Our ability to obtain additional financing; and


•	The restrictions imposed by our financing agreements on our operations.

-51-


ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to changes in interest rates because our Senior Secured Credit Facility is variable rate debt. Interest rate changes generally do not affect the market value of our Senior Secured Credit Facility, but do affect the amount of our interest payments and, therefore, our future earnings and cash flows, assuming other factors are held constant. At December 31, 2011, we had variable rate debt of approximately $184.0 million related to our Senior Secured Credit Facility.

Holding other variables constant, including levels of indebtedness, a one percentage point increase in interest rates on our variable rate debt would have an adverse impact on pre-tax earnings and cash flows for the remaining three months in the fiscal year ending March 31, 2012 by approximately $0.5 million.

On January 31, 2012, in connection with our acquisition of 15 North American over-the-counter healthcare brands from GlaxoSmithKline plc and its affiliates, (i) we paid in full all of our obligations under our existing Senior Secured Credit Facility and terminated the credit agreement governing such facility; and (ii) entered into a new senior secured credit facility which is described in Note 22 to our Consolidated Financial Statements contained elsewhere in this Quarterly Report on Form 10-Q.


ITEM 4.	CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

The Company's management, with the participation of its Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the Company's disclosure controls and procedures, as defined in Rule 13a–15(e) of the Securities Exchange Act of 1934 (“Exchange Act”), as of December 31, 2011. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that, as of December 31, 2011, the Company's disclosure controls and procedures were effective to ensure that information required to be disclosed by the Company in the reports the Company files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to the Company's management, including the Company's Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There have been no changes during the quarter ended December 31, 2011 in the Company's internal control over financial reporting, as defined in Rule 13a-15(f) of the Exchange Act, that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.


PART II.	OTHER INFORMATION


ITEM 1.	LEGAL PROCEEDINGS

Each of (i) Part I, Item 3 in our Annual Report on Form 10-K for the fiscal year ended March 31, 2011 and (ii) Part II, Item 1 in our Quarterly Reports on Form 10-Q for the fiscal quarters ended June 30, 2011 and September 30, 2011 is incorporated herein by this reference.

Trutek Arbitration

Closing arguments for the arbitration were made on November 30, 2011. We received a written decision from the arbitration panel on January 30, 2012 in which the panel denied all of Trutek Corp.'s claims in the arbitration.


ITEM 6.	EXHIBITS

See Exhibit Index immediately following the signature page.

-52-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



		PRESTIGE BRANDS HOLDINGS, INC.


Date:	February 9, 2012	By:	/s/ RONALD M. LOMBARDI
			Ronald M. Lombardi
			Chief Financial Officer
			(Principal Financial Officer and
			Duly Authorized Officer)

-53-

Exhibit Index




2.1			Business Sale and Purchase Agreement, dated December 20, 2011, between GlaxoSmithKline LLC, GlaxoSmithKline plc and certain of its affiliates described in Schedule 1 thereto and Prestige Brands Holdings, Inc. (incorporated by reference to Exhibit 2.1 to the Form 8-K filed by Prestige Brands Holdings, Inc. on December 27, 2011).+

2.2			Business Sale and Purchase Agreement, dated as of December 20, 2011, between GlaxoSmithKline LLC, GlaxoSmithKline Consumer Healthcare L.P., GlaxoSmithKline plc and Prestige Brands Holdings, Inc. (incorporated by reference to Exhibit 2.2 to the Form 8-K filed by Prestige Brands Holdings, Inc. on December 27, 2011).+

10.1			Commitment Letter, dated December 20, 2011, by and among Citibank Global Markets, Inc., Morgan Stanley Senior Funding, Inc., Royal Bank of Canada and Prestige Brands Holdings, Inc. (incorporated by reference to Exhibit 10.1 to the Form 8-K filed by Prestige Brands Holdings, Inc. on December 27, 2011).

31.1			Certification of Principal Executive Officer of Prestige Brands Holdings, Inc. pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.

31.2			Certification of Principal Financial Officer of Prestige Brands Holdings, Inc. pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.

32.1			Certification of Principal Executive Officer of Prestige Brands Holdings, Inc. pursuant to Rule 13a-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code.

32.2			Certification of Principal Financial Officer of Prestige Brands Holdings, Inc. pursuant to Rule 13a-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code.
101.INS*			XBRL Instance Document
101.SCH*			XBRL Taxonomy Extension Schema Document
101.CAL*			XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*			XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*			XBRL Taxonomy Extension Label Linkbase Document
101.PRE*			XBRL Taxonomy Extension Presentation Linkbase Document

+ Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the Commission under Rule 24b-2 under the Securities Exchange Act of 1934, as amended. The confidential treatment request was granted by the Commission on January 18, 2012. The omitted confidential material has been filed separately with the Securities and Exchange Commission. The location of the confidential information is indicated in the exhibit with brackets and asterisks ([***] ).

* XBRL information is furnished and not filed for purposes of Section 11 and 12 of the Securities Act of 1933 and Section 18 of the Securities Exchange Act of 1934, and is not subject to liability under those sections, is not part of any registration statement, prospectus or other document to which it relates and is not incorporated or deemed to be incorporated by reference into any registration statement, prospectus or other document.

-54-

Exhibit 31.1 20111231

Exhibit 31.1

CERTIFICATIONS

I, Matthew M. Mannelly, certify that:


1.	I have reviewed this Quarterly Report on Form 10-Q of Prestige Brands Holdings, Inc.;


2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;


3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;


4.	The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:


a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;


b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;


c.	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


d.	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and


5.	The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):


a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and


b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.



Date:	February 9, 2012	/s/ Matthew M. Mannelly
		Matthew M. Mannelly
		Chief Executive Officer
		(Principal Executive Officer)

Exhibit 31.2 20111231

Exhibit 31.2

CERTIFICATIONS

I, Ronald M. Lombardi, certify that:


1.	I have reviewed this Quarterly Report on Form 10-Q of Prestige Brands Holdings, Inc.;


2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;


3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;


4.	The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:


a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;


b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;


c.	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


d.	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and


5.	The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):


a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and


b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.



Date:	February 9, 2012	/s/ Ronald M. Lombardi
		Ronald M. Lombardi
		Chief Financial Officer
		(Principal Financial Officer)

Exhibit 32.1 20111231

EXHIBIT 32.1

CERTIFICATION

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Matthew M. Mannelly, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Prestige Brands Holdings, Inc. on Form 10-Q for the quarter ended December 31, 2011, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as applicable, and that information contained in such Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of Prestige Brands Holdings, Inc.

/s/ Matthew M. Mannelly

Name: Matthew M. Mannelly

Title: Chief Executive Officer

(Principal Executive Officer)

Date: February 9, 2012

Exhibit 32.2 20111231

EXHIBIT 32.2

CERTIFICATION

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Ronald M. Lombardi, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Prestige Brands Holdings, Inc. on Form 10-Q for the quarter ended December 31, 2011, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as applicable, and that information contained in such Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of Prestige Brands Holdings, Inc.



/s/ Ronald M. Lombardi
Name: Ronald M. Lombardi
Title: Chief Financial Officer
(Principal Financial Officer)
Date: February 9, 2012

Primary IR Contact

Irinquiries@prestigebrands.com
Prestige Consumer Healthcare Inc.
660 White Plains Road – Ste 250
Tarrytown, NY 10591
Telephone: 914-524-6819

Transfer Agent

AST
6201 15th Avenue
Brooklyn, NY 11219
Telephone: (800) 937-5449
help@astfinancial.com
https://www.astfinancial.com

Stay up to date with investor news, stock information and SEC filings.
Subscribe »